Header Logo

JAFFER A AJANI

TitleProfessor
InstitutionMD Anderson
DepartmentGI Medical Oncology
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Fan Y, Song S, Li Y, Dhar SS, Jin J, Yoshimura K, Yao X, Wang R, Scott AW, Pool Pizzi M, Wu J, Ma L, Calin GA, Hanash S, Wang L, Curran M, Ajani JA. Galectin-3 Cooperates with CD47 to Suppress Phagocytosis and T cell Immunity in Gastric Cancer Peritoneal Metastases. Cancer Res. 2023 Sep 22. PMID: 37738407.
      Citations:    Fields:    
    2. Moehler M, Xiao H, Blum SI, Elimova E, Cella D, Shitara K, Ajani JA, Janjigian YY, Garrido M, Shen L, Yamaguchi K, Liu T, Schenker M, Kowalyszyn R, Bragagnoli AC, Bruges R, Montesarchio V, Pazo-Cid R, Hunter S, Davenport E, Wang J, Kondo K, Li M, Wyrwicz L. Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649. J Clin Oncol. 2023 Sep 15; JCO2300170. PMID: 37713657.
      Citations:    Fields:    
    3. Jeong YS, Eun YG, Lee SH, Kang SH, Yim SY, Kim EH, Noh JK, Sohn BH, Woo SR, Kong M, Nam DH, Jang HJ, Lee HS, Song S, Oh SC, Lee J, Ajani JA, Lee JS. Clinically conserved genomic subtypes of gastric adenocarcinoma. Mol Cancer. 2023 Sep 06; 22(1):147. PMID: 37674200; PMCID: PMC10481468.
      Citations:    Fields:    Translation:HumansCells
    4. Jin J, Yoshimura K, Sewastjanow-Silva M, Song S, Ajani JA. Challenges and Prospects of Patient-Derived Xenografts for Cancer Research. Cancers (Basel). 2023 Aug 31; 15(17). PMID: 37686627; PMCID: PMC10486659.
      Citations:    
    5. DiPeri TP, Kong K, Varadarajan K, Karp DD, Ajani JA, Pant S, Press MF, Piha-Paul SA, Dumbrava EE, Meric-Bernstam F, DiPeri TP, Kong K, Varadarajan K, Karp DD, Ajani JA, Pant S, Press MF, Piha-Paul SA, Dumbrava EE, Meric-Bernstam F. Discordance of HER2 Expression and/or Amplification on Repeat Testing. Mol Cancer Ther. 2023 Aug 01; 22(8):976-984. PMID: 37339271.
      Citations:    Fields:    
    6. Hirata Y, Agnes A, Estrella JS, Blum M, Das P, Minsky BD, Ajani JA, Badgwell BD, Mansfield P, Ikoma N. ASO Visual Abstract: Clinical Impact of Positive Surgical Margins in Gastric Adenocarcinoma in the Era of Preoperative Therapy. Ann Surg Oncol. 2023 Aug; 30(8):4948-4949. PMID: 37193894.
      Citations: 1     Fields:    
    7. Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, Lordick F, Van Cutsem E, Gallego Plazas J, Huang J, Shen L, Oh SC, Sunpaweravong P, Soo Hoo HF, Turk HM, Oh M, Park JW, Moran D, Bhattacharya P, Arozullah A, Xu RH. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023 08; 29(8):2133-2141. PMID: 37524953; PMCID: PMC10427418.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    8. Wang R, Song S, Qin J, Yoshimura K, Peng F, Chu Y, Li Y, Fan Y, Jin J, Dang M, Dai E, Pei G, Han G, Hao D, Li Y, Chatterjee D, Harada K, Pizzi MP, Scott AW, Tatlonghari G, Yan X, Xu Z, Hu C, Mo S, Shanbhag N, Lu Y, Sewastjanow-Silva M, Fouad Abdelhakeem AA, Peng G, Hanash SM, Calin GA, Yee C, Mazur P, Marsden AN, Futreal A, Wang Z, Cheng X, Ajani JA, Wang L. Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression. Cancer Cell. 2023 08 14; 41(8):1407-1426.e9. PMID: 37419119.
      Citations:    Fields:    Translation:HumansCells
    9. Trail A, Rogers J, Ajani J. Can You Establish the Cause of This Patient's Shortness of Breath? J Adv Pract Oncol. 2023 Jul; 14(5):440-443. PMID: 37576362; PMCID: PMC10414527.
      Citations:    
    10. Van Cutsem E, di Bartolomeo M, Smyth E, Chau I, Park H, Siena S, Lonardi S, Wainberg ZA, Ajani J, Chao J, Janjigian Y, Qin A, Singh J, Barlaskar F, Kawaguchi Y, Ku G. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023 Jul; 24(7):744-756. PMID: 37329891.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    11. DiPeri TP, Evans KW, Raso MG, Zhao M, Rizvi YQ, Zheng X, Wang B, Kirby BP, Kong K, Kahle M, Yap TA, Ileana Dumbrava EE, Ajani JA, Fu S, Keyomarsi K, Meric-Bernstam F. Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. Clin Cancer Res. 2023 Jun 06. PMID: 37279095.
      Citations:    Fields:    
    12. Ko AH, Kim KP, Siveke JT, Lopez CD, Lacy J, O'Reilly EM, Macarulla T, Manji GA, Lee J, Ajani J, Alsina Maqueda M, Rha SY, Lau J, Al-Sakaff N, Allen S, Lu D, Shemesh CS, Gan X, Cha E, Oh DY. Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform. Oncologist. 2023 06 02; 28(6):553-e472. PMID: 36940261; PMCID: PMC10243783.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    13. Hirata Y, Noorani A, Song S, Wang L, Ajani JA. Early stage gastric adenocarcinoma: clinical and molecular landscapes. Nat Rev Clin Oncol. 2023 07; 20(7):453-469. PMID: 37264184.
      Citations: 1     Fields:    Translation:HumansCells
    14. Chu Y, Dai E, Li Y, Han G, Pei G, Ingram DR, Thakkar K, Qin JJ, Dang M, Le X, Hu C, Deng Q, Sinjab A, Gupta P, Wang R, Hao D, Peng F, Yan X, Liu Y, Song S, Zhang S, Heymach JV, Reuben A, Elamin YY, Pizzi MP, Lu Y, Lazcano R, Hu J, Li M, Curran M, Futreal A, Maitra A, Jazaeri AA, Ajani JA, Swanton C, Cheng XD, Abbas HA, Gillison M, Bhat K, Lazar AJ, Green M, Litchfield K, Kadara H, Yee C, Wang L. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nat Med. 2023 Jun; 29(6):1550-1562. PMID: 37248301.
      Citations: 2     Fields:    Translation:HumansCells
    15. Zhao S, Wang R, Song S, Hao D, Han G, Song X, Zhang J, Pizzi MP, Shanbhag N, Futreal A, Badgwell B, Harada K, Calin G, Vykoukal J, Yu CY, Katayama H, Hanash SM, Wang L, Ajani JA. Proteogenomic landscape of gastric adenocarcinoma peritoneal metastases. iScience. 2023 Jun 16; 26(6):106913. PMID: 37305699; PMCID: PMC10251128.
      Citations:    
    16. Rogers JE, Yamashita K, Sewastjanow-Silva M, Rosa Vicentini E, Waters R, Ajani JA. Nivolumab combination therapy as first-line treatments for unresectable, advanced or metastatic esophageal squamous cell carcinoma. Expert Rev Anticancer Ther. 2023 06; 23(6):565-571. PMID: 37122102.
      Citations:    Fields:    Translation:Humans
    17. Li JJ, Rogers JE, Yamashita K, Waters RE, Blum Murphy M, Ajani JA. Therapeutic Advances in the Treatment of Gastroesophageal Cancers. Biomolecules. 2023 05 06; 13(5). PMID: 37238666; PMCID: PMC10216443.
      Citations:    Fields:    Translation:Humans
    18. Hirata Y, Agnes A, Estrella JS, Blum Murphy M, Das P, Minsky BD, Ajani JA, Badgwell BD, Mansfield P, Ikoma N. Clinical Impact of Positive Surgical Margins in Gastric Adenocarcinoma in the Era of Preoperative Therapy. Ann Surg Oncol. 2023 Aug; 30(8):4936-4945. PMID: 37106276.
      Citations:    Fields:    Translation:Humans
    19. Mitchell KG, Bayley EM, Ikoma N, Antonoff MB, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Maru DM, Erasmus JJ, Weston BR, Ajani JA, Badgwell BD, Hofstetter WL. Gastric Extent of Tumor Predicts Peritoneal Metastasis in Siewert II Adenocarcinoma. Ann Thorac Surg. 2023 Apr 18. PMID: 37080372.
      Citations:    Fields:    
    20. Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, Van Cutsem E, Xu RH, Aprile G, Xu J, Chao J, Pazo-Cid R, Kang YK, Yang J, Moran D, Bhattacharya P, Arozullah A, Park JW, Oh M, Ajani JA. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023 05 20; 401(10389):1655-1668. PMID: 37068504.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    21. Gengyi Z, Yuanjian H, Zhang S, Ko KP, Kim BJ, Zhang J, Pizzi MP, Fan Y, Jun S, Niu N, Wang H, Song S, Ajani JA, Park JI. CDH1 loss promotes diffuse-type gastric cancer tumorigenesis via epigenetic reprogramming and immune evasion. bioRxiv. 2023 Apr 04. PMID: 36993615; PMCID: PMC10055394.
      Citations:    
    22. Ajani JA, D'Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Farjah F, Gerdes H, Gibson M, Grierson P, Hofstetter WL, Ilson DH, Jalal S, Keswani RN, Kim S, Kleinberg LR, Klempner S, Lacy J, Licciardi F, Ly QP, Matkowskyj KA, McNamara M, Miller A, Mukherjee S, Mulcahy MF, Outlaw D, Perry KA, Pimiento J, Poultsides GA, Reznik S, Roses RE, Strong VE, Su S, Wang HL, Wiesner G, Willett CG, Yakoub D, Yoon H, McMillian NR, Pluchino LA. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 04; 21(4):393-422. PMID: 37015332.
      Citations: 5     Fields:    Translation:Humans
    23. Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Wyrwicz L, Yamaguchi K, Skoczylas T, Bragagnoli AC, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA. A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus. Future Oncol. 2023 Apr; 19(11):739-752. PMID: 36919706.
      Citations:    Fields:    Translation:Humans
    24. Xu C, Huang KK, Law JH, Chua JS, Sheng T, Flores NM, Pizzi MP, Okabe A, Tan ALK, Zhu F, Kumar V, Lu X, Benitez AM, Lian BSX, Ma H, Ho SWT, Ramnarayanan K, Anene-Nzelu CG, Razavi-Mohseni M, Abdul Ghani SAB, Tay ST, Ong X, Lee MH, Guo YA, Ashktorab H, Smoot D, Li S, Skanderup AJ, Beer MA, Foo RSY, Wong JSH, Sanghvi K, Yong WP, Sundar R, Kaneda A, Prabhakar S, Mazur PK, Ajani JA, Yeoh KG, So JB, Tan P, Singapore Gastric Cancer Consortium. Comprehensive molecular phenotyping of ARID1A-deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities. Gut. 2023 09; 72(9):1651-1663. PMID: 36918265.
      Citations:    Fields:    Translation:Humans
    25. Rogers JE, Ajani JA. Recent advances in the management of gastric adenocarcinoma patients. Fac Rev. 2023; 12:2. PMID: 36873983; PMCID: PMC9975945.
      Citations:    
    26. Jin J, Huo L, Fan Y, Wang R, Scott AW, Pizzi MP, Yao X, Shao S, Ma L, Da Silva MS, Yamashita K, Yoshimura K, Zhang B, Wu J, Wang L, Song S, Ajani JA. A new intronic quantitative PCR method led to the discovery of transformation from human ascites to murine malignancy in a mouse model. Front Oncol. 2023; 13:1062424. PMID: 36865791; PMCID: PMC9972586.
      Citations: 1     
    27. Yoon HH, Shi Q, Ajani JA. Tissue-Based PD-L1 Expression Is the Strongest Predictor of Overall Survival Benefit From ICI in Advanced Gastroesophageal Cancer-Reply. JAMA Oncol. 2023 02 01; 9(2):280-281. PMID: 36547945.
      Citations:    Fields:    Translation:Humans
    28. Janku F, Han SW, Doi T, Amatu A, Ajani JA, Kuboki Y, Cortez A, Cellitti SE, Mahling PC, Subramanian K, Schoenfeld HA, Choi SM, Iaconis LA, Lee LH, Pelletier MR, Dranoff G, Askoxylakis V, Siena S. Preclinical Characterization and Phase I Study of an Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies. Cancer Immunol Res. 2022 Dec 02; 10(12):1441-1461. PMID: 36129967.
      Citations:    
    29. Kharofa JR, Yothers G, Kachnic LA, Ajani J, Meyer JE, Augspurger ME, Okawara GS, Garg MK, Schefter TE, Swanson TA, Doncals DE, Kim H, Zaki BI, Narayan S, Lee RJ, Mamon HJ, Schwartz MA, Moughan J, Crane CH. Use of the Toxicity Index in Evaluating Adverse Events in Anal Cancer Trials: Analysis of RTOG 9811 and RTOG 0529. Am J Clin Oncol. 2022 12 01; 45(12):534-536. PMID: 36413683; PMCID: PMC9912479.
      Citations:    Fields:    Translation:Humans
    30. Vassilakopoulou M, Chen HC, Wang X, Harada K, Iwatsuki M, Das P, Blum Murphy M, Matamoros A, Sagebiel T, Devine C, Thomas I, Sanders EM, Shanbhag N, Rogers JE, Lee JH, Weston B, Bhutani MS, Hofstetter W, Nguyen QN, Badgwell BD, Ajani JA. Localized Gastroesophageal Adenocarcinoma in the Elderly: Is Age a Factor Associated with Suboptimal Treatment? Oncology. 2023; 101(3):153-158. PMID: 36412619.
      Citations:    Fields:    Translation:Humans
    31. Rogers JE, Ajani JA. Perspectives on the pharmacological management of esophageal cancer: where are we now and where do we need to go? Expert Opin Pharmacother. 2022 Dec; 23(17):1893-1902. PMID: 36286544.
      Citations:    Fields:    Translation:Humans
    32. Sewastjanow-Silva M, Yamashita K, Rosa Vicentini E, Hirschmann M, Pool Pizzi M, Trail AM, Waters RE, Rogers JE, Ajani JA. Nivolumab with or without chemotherapy for metastatic gastroesophageal cancers and future perspectives. Expert Rev Anticancer Ther. 2022 Nov; 22(11):1177-1181. PMID: 36266061.
      Citations:    Fields:    Translation:Humans
    33. Vo HH, Fu S, Hong DS, Karp DD, Piha-Paul S, Subbiah V, Janku F, Naing A, Yap TA, Rodon J, Ajani JA, Cartwright C, Johnson A, Song IW, Beck J, Kahle M, Nogueras-Gonzalez GM, Miller V, Chao C, Vining DJ, Berry DA, Meric-Bernstam F, Tsimberidou AM. Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology. NPJ Precis Oncol. 2022 Oct 27; 6(1):78. PMID: 36302890; PMCID: PMC9612600.
      Citations: 1     
    34. Yoon HH, Jin Z, Kour O, Kankeu Fonkoua LA, Shitara K, Gibson MK, Prokop LJ, Moehler M, Kang YK, Shi Q, Ajani JA. Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials. JAMA Oncol. 2022 10 01; 8(10):1456-1465. PMID: 36006624; PMCID: PMC9412834.
      Citations:    
    35. Rogers JE, Yamashita K, Sewastjanow Silva M, Ajani JA. Current Immune Checkpoint Inhibitor Genetic Biomarker Exploration in Gastrointestinal Tumors. Cancers (Basel). 2022 Sep 30; 14(19). PMID: 36230726; PMCID: PMC9563283.
      Citations:    
    36. Tabernero J, Shen L, Elimova E, Ku G, Liu T, Shitara K, Lin X, Boyken L, Li H, Grim J, Ajani J. HERIZON-GEA-01: Zanidatamab + chemo?? tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma. Future Oncol. 2022 Sep; 18(29):3255-3266. PMID: 36000541.
      Citations:    
    37. Fan Y, Li Y, Yao X, Jin J, Scott A, Liu B, Wang S, Huo L, Wang Y, Wang R, Pool Pizzi M, Ma L, Shao S, Sewastjanow-Silva M, Waters R, Chatterjee D, Liu B, Shanbhag N, Peng G, Calin GA, Mazur PK, Hanash SM, Ishizawa J, Hirata Y, Nagano O, Wang Z, Wang L, Xian W, McKeon F, Ajani JA, Song S. Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment. Gut. 2023 04; 72(4):624-637. PMID: 36002248.
      Citations:    
    38. Li Y, Fan Y, Xu J, Huo L, Scott AW, Jin J, Yang B, Shao S, Ma L, Wang Y, Yao X, Pool Pizzi M, Sewastjanow Da Silva M, Zhang G, Zhuo L, Cho EJ, Dalby KN, Shanbhag ND, Wang Z, Li W, Song S, Ajani JA. GRK3 is a poor prognosticator and serves as a therapeutic target in advanced gastric adenocarcinoma. J Exp Clin Cancer Res. 2022 Aug 23; 41(1):257. PMID: 35996148; PMCID: PMC9396876.
      Citations:    
    39. Weng J, Ajani JA, Murphy MB, Badgwell BD, Tchakarov AS, Mamlouk O, Das P. Immunotherapy Recall: Chemoradiation-Induced Reactivation of Immune Checkpoint Inhibitor Nephritis. JCO Precis Oncol. 2022 08; 6:e2200049. PMID: 35952321.
      Citations:    
    40. Van Cutsem E, Kato K, Ajani J, Shen L, Xia T, Ding N, Zhan L, Barnes G, Kim SB. Tislelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of life. ESMO Open. 2022 08; 7(4):100517. PMID: 35785595; PMCID: PMC9434166.
      Citations:    
    41. Kumar S, Bahdi F, Emelogu IK, Yu AC, Coronel M, Ge PS, Coronel E, Ajani JA, Weston B, Lynch P, Ross WA, Lee JH. How much progress have we made?: a 20-year experience regarding esophageal stents for the palliation of malignant dysphagia. Dis Esophagus. 2022 Jun 15; 35(6). PMID: 34937091.
      Citations:    Fields:    Translation:Humans
    42. Rogers JE, Ajani JA. Defining the role of upfront immune checkpoint inhibition in advanced HER-2 negative gastric or gastroesophageal junction adenocarcinoma. Ann Palliat Med. 2022 06; 11(6):2180-2183. PMID: 35695051.
      Citations:    Fields:    Translation:Humans
    43. Rha SY, Ku GY, Kim HS, Chung HC, Amlashi FG, Maru DM, Fein CA, Tang LH, Zhou W, Wu T, Peter SA, Kelsen DP, Ajani JA. PD-L1 expression and overall survival in Asian and western patients with gastric cancer. Future Oncol. 2022 Jul; 18(21):2623-2634. PMID: 35616013.
      Citations:    Fields:    Translation:Humans
    44. Ajani JA, Leung L, Singh P, Kurt M, Kim I, Pourrahmat MM, Kanters S. Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis. Eur J Cancer. 2022 07; 170:119-130. PMID: 35605522.
      Citations:    Fields:    Translation:Humans
    45. Shen L, Kato K, Kim SB, Ajani JA, Zhao K, He Z, Yu X, Shu Y, Luo Q, Wang J, Chen Z, Niu Z, Zhang L, Yi T, Sun JM, Chen J, Yu G, Lin CY, Hara H, Bi Q, Satoh T, Pazo-Cid R, Arkenau HT, Lordick F, Li L, Ding N, Tao A, Shi J, Van Cutsem E, RATIONALE-302 Investigators, Borg C. Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. J Clin Oncol. 2022 09 10; 40(26):3065-3076. PMID: 35442766; PMCID: PMC9462531.
      Citations: 4     Fields:    
    46. Shitara K, Ajani JA, Moehler M, Shen L, Yamaguchi K, Wyrwicz L, Bragagnoli AC, Liu T, Tehfe M, Elimova E, Kowalyszyn R, Pazo-Cid R, Schenker M, Cleary JM, Yanez P, Feeney K, Karamouzis MV, Poulart V, Lei M, Xiao H, Kondo K, Li M, Janjigian YY, Garrido M, Gallardo C, Skoczylas T, Bruges R, Zander T, de Azevedo S. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022 03; 603(7903):942-948. PMID: 35322232; PMCID: PMC8967713.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    47. van der Wilk BJ, Eyck BM, Hofstetter WL, Ajani JA, Piessen G, Castoro C, Alfieri R, Kim JH, Kim SB, Furlong H, Walsh TN, Nieboer D, Wijnhoven BPL, Lagarde SM, Lanschot JJBV. Chemoradiotherapy Followed by Active Surveillance Versus Standard Esophagectomy for Esophageal Cancer: A Systematic Review and Individual Patient Data Meta-analysis. Ann Surg. 2022 03 01; 275(3):467-476. PMID: 34191461.
      Citations:    Fields:    Translation:Humans
    48. Harada K, Yamashita K, Iwatsuki M, Baba H, Ajani JA. Intraperitoneal therapy for gastric cancer peritoneal carcinomatosis. Expert Rev Clin Pharmacol. 2022 Jan; 15(1):43-49. PMID: 35184625.
      Citations:    Fields:    Translation:Humans
    49. Shah MA, Udrea AA, Bondarenko I, Mansoor W, Sarosiek T, Bozzarelli S, Schenker M, Gomez-Martin C, Morgan C, Pikiel J, Kalofonos HP, Wojcik E, Buchler T, Swinson D, Cicin I, Joseph M, Vynnychenko I, Luft AV, Enzinger PC, Salek T, Papandreou C, Maiello E, Wei R, Ferry D, Gao L, Oliveira JM, Ajani JA, S?nchez RG, ?zg?roglu M, Tournigand C. Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. Cancers (Basel). 2022 Feb 24; 14(5). PMID: 35267477; PMCID: PMC8909008.
      Citations:    
    50. Fu L, Yonemura A, Yasuda-Yoshihara N, Umemoto T, Zhang J, Yasuda T, Uchihara T, Akiyama T, Kitamura F, Yamashita K, Okamoto Y, Bu L, Wei F, Hu X, Liu Y, Ajani JA, Tan P, Baba H, Ishimoto T. Intracellular MUC20 variant 2 maintains mitochondrial calcium homeostasis and enhances drug resistance in gastric cancer. Gastric Cancer. 2022 05; 25(3):542-557. PMID: 35166958.
      Citations:    Fields:    Translation:HumansAnimals
    51. Rogers JE, Sewastjanow-Silva M, Waters RE, Ajani JA. Esophageal cancer: emerging therapeutics. Expert Opin Ther Targets. 2022 02; 26(2):107-117. PMID: 35119973.
      Citations:    Fields:    Translation:Humans
    52. CheckMate 648 Trial Investigators, Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Ostoich SA, Kim HR, Ueno M, Mansoor W, Yang WC, Liu T, Bridgewater J, Makino T, Xynos I, Liu X, Lei M, Kondo K, Patel A, Gricar J, Chau I, Kitagawa Y. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med. 2022 02 03; 386(5):449-462. PMID: 35108470.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    53. Rogers JE, Trail A, Ajani JA. Localized Gastroesophageal Cancers: Can We Shift the Current Treatment Paradigms? J Natl Compr Canc Netw. 2022 02; 20(2):100-101. PMID: 35130497.
      Citations:    Fields:    Translation:Humans
    54. Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, Farjah F, Gerdes H, Gibson MK, Hochwald S, Hofstetter WL, Ilson DH, Keswani RN, Kim S, Kleinberg LR, Klempner SJ, Lacy J, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Outlaw D, Park H, Perry KA, Pimiento J, Poultsides GA, Reznik S, Roses RE, Strong VE, Su S, Wang HL, Wiesner G, Willett CG, Yakoub D, Yoon H, McMillian N, Pluchino LA. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 02; 20(2):167-192. PMID: 35130500.
      Citations: 16     Fields:    Translation:Humans
    55. Rogers JE, Sewastjanow D Silva M, Waters RE, Ajani JA. Pharmaceutical advances in the treatment of gastric adenocarcinoma. Expert Opin Pharmacother. 2022 Apr; 23(5):611-621. PMID: 35098851.
      Citations:    Fields:    Translation:Humans
    56. De Silva Sewastjanow M, Rogers JE, Hofstetter WL, Ajani JA. Esophageal cancer: Is the CROSS strategy ready for history books? J Thorac Cardiovasc Surg. 2022 Jan 22. PMID: 35184889.
      Citations:    Fields:    
    57. Charalampakis N, Tsakatikas S, Schizas D, Kykalos S, Tolia M, Fioretzaki R, Papageorgiou G, Katsaros I, Abdelhakeem AAF, Sewastjanow-Silva M, Rogers JE, Ajani JA. Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives. World J Gastrointest Oncol. 2022 Jan 15; 14(1):181-202. PMID: 35116110; PMCID: PMC8790425.
      Citations:    
    58. Fan Y, Ajani JA, Song S. Proteomic profiling of key signatures from gastric lesions to early gastric cancer. EBioMedicine. 2021 Dec; 74:103744. PMID: 34902787; PMCID: PMC8671089.
      Citations:    Fields:    Translation:Humans
    59. Siegel EM, Ajidahun A, Berglund A, Guerrero W, Eschrich S, Putney RM, Magliocco A, Riggs B, Winter K, Simko JP, Ajani JA, Guha C, Okawara GS, Abdalla I, Becker MJ, Pizzolato JF, Crane CH, Brown KD, Shibata D. Genome-wide host methylation profiling of anal and cervical carcinoma. PLoS One. 2021; 16(12):e0260857. PMID: 34882728; PMCID: PMC8659695.
      Citations: 2     Fields:    Translation:HumansCells
    60. Zhou N, Hofstetter WL, Esophageal Squamous Cell Carcinoma Working Group, Mitchell KG, Bayley EM, Ajani JA, Antonoff MB, Betancourt SL, Blum-Murphy M, Feldman HA, Lin SH, Maru DM, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Weston BR. Salvage Esophagectomy Definition Influences Comparative Outcomes in Esophageal Squamous Cell Cancers. Ann Thorac Surg. 2022 12; 114(6):2032-2040. PMID: 34883083.
      Citations:    Fields:    
    61. Rogers JE, Wang X, Trail A, Ajani JA. Beyond Front-Line Therapy for Unresectable Gastroesophageal Adenocarcinoma: Are There Differences in Subsequent Therapy Sequencing? Oncology. 2022; 100(3):182-187. PMID: 34969028.
      Citations:    Fields:    Translation:Humans
    62. VanderWalde N, Moughan J, Lichtman SM, Jagsi R, Ballo M, VanderWalde A, Mohiuddin M, Meropol NJ, Kachnic L, Berger A, Ajani J, Anne R, Hopkins JL, Arora A, Meyer J, Ellsworth SG, Lee RJ, Green N, Crane CH. The association of age with acute toxicities in NRG oncology combined modality lower GI cancer trials. J Geriatr Oncol. 2022 04; 13(3):294-301. PMID: 34756496; PMCID: PMC8967782.
      Citations:    Fields:    Translation:Humans
    63. Zhou N, Mitchell KG, Corsini EM, Truong VTT, Antonoff MB, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Ajani JA, Hofstetter WL. Analysis of trimodal and bimodal therapy in a selective-surgery paradigm for locally advanced oesophageal squamous cell carcinoma. Br J Surg. 2021 10 23; 108(10):1207-1215. PMID: 34095952.
      Citations:    Fields:    Translation:Humans
    64. Erstad DJ, Blum M, Estrella JS, Das P, Minsky BD, Ajani JA, Mansfield PF, Ikoma N, Badgwell BD. Navigating Nodal Metrics for Node-Positive Gastric Cancer in the United States: An NCDB-Based Study and Validation of AJCC Guidelines. J Natl Compr Canc Netw. 2021 Oct 22; 1-12. PMID: 34678759.
      Citations: 1     Fields:    
    65. Allen CJ, Pointer DT, Blumenthaler AN, Mehta RJ, Hoffe SE, Minsky BD, Smith GL, Blum M, Mansfield PF, Ikoma N, Das P, Ajani J, Dineen SP, Fleming JB, Badgwell BD, Pimiento JM. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma: A Multi-institutional Analysis. Ann Surg. 2021 10 01; 274(4):544-548. PMID: 34132693; PMCID: PMC8988446.
      Citations: 1     Fields:    Translation:Humans
    66. Han G, Yang G, Hao D, Lu Y, Thein K, Simpson BS, Chen J, Sun R, Alhalabi O, Wang R, Dang M, Dai E, Zhang S, Nie F, Zhao S, Guo C, Hamza A, Czerniak B, Cheng C, Siefker-Radtke A, Bhat K, Futreal A, Peng G, Wargo J, Peng W, Kadara H, Ajani J, Swanton C, Litchfield K, Ahnert JR, Gao J, Wang L. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun. 2021 09 23; 12(1):5606. PMID: 34556668; PMCID: PMC8460828.
      Citations: 13     Fields:    Translation:HumansCells
    67. Cameron RB, Ajani JA, Wu AJ. Adjuvant nivolumab after preoperative chemoradiotherapy and surgery in esophageal cancer: A shifting paradigm. J Thorac Cardiovasc Surg. 2022 08; 164(2):433-437. PMID: 34663521.
      Citations:    Fields:    Translation:Humans
    68. Abdelhakeem A, Patnana M, Wang X, Rogers JE, Murphy MB, Sagebiel T, Ikoma N, Badgwell BD, Trail A, Estrella JS, Lu Y, Devine C, Ajani JA. Influence of Baseline Positron Emission Tomography in Metastatic Gastroesophageal Cancer on Survival and Response to Therapy. Oncology. 2021; 99(10):659-664. PMID: 34352788.
      Citations:    Fields:    Translation:Humans
    69. Ajani JA. Impediments to therapeutic advances for patients with gastroesophageal adenocarcinoma. Transl Gastroenterol Hepatol. 2021; 6:49. PMID: 34423170; PMCID: PMC8343420.
      Citations:    
    70. Jin Z, Shen J, Wang C, Chen D, Zhang B, Zhang J, Ajani JA, Bennouna J, Chao J, Yoon HH, Zhu H, Ruan Y, Zhu C, Xu A. Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook. Ann Transl Med. 2021 Jul; 9(14):1189. PMID: 34430630; PMCID: PMC8350624.
      Citations: 3     
    71. Song S, Xu Y, Huo L, Zhao S, Wang R, Li Y, Scott AW, Pizzi MP, Wang Y, Fan Y, Harada K, Jin J, Ma L, Yao X, Shanbhag ND, Gan Q, Roy-Chowdhuri S, Badgwell BD, Wang Z, Wang L, Ajani JA. Patient-derived cell lines and orthotopic mouse model of peritoneal carcinomatosis recapitulate molecular and phenotypic features of human gastric adenocarcinoma. J Exp Clin Cancer Res. 2021 Jun 23; 40(1):207. PMID: 34162421; PMCID: PMC8223395.
      Citations:    Fields:    Translation:HumansAnimalsCells
    72. Janjigian YY, Shitara K, Moehler M, Shen L, Wyrwicz L, Yamaguchi K, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA, Garrido M, Salman P, Skoczylas T, Bruges R, Zander T. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021 07 03; 398(10294):27-40. PMID: 34102137; PMCID: PMC8436782.
      Citations: 151     Fields:    Translation:HumansCTClinical Trials
    73. Shin MK, Kim J, Kim D, Lee SH, Shin JH, Jeong YS, Sohn BH, Kim J, Kim SR, Ajani JA, Lee JS, Cheong JH. Long non-coding RNAs are significantly associated with prognosis and response to therapies in gastric cancer. Clin Transl Med. 2021 06; 11(6):e421. PMID: 34185430; PMCID: PMC8181196.
      Citations:    Fields:    Translation:Humans
    74. Jabbour SK, Williams TM, Sayan M, Miller ED, Ajani JA, Chang AC, Coleman N, El-Rifai W, Haddock M, Ilson D, Jamorabo D, Kunos C, Lin S, Liu G, Prasanna PG, Rustgi AK, Wong R, Vikram B, Ahmed MM. Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies. J Natl Cancer Inst. 2021 06 01; 113(6):665-679. PMID: 33351071; PMCID: PMC8600025.
      Citations: 1     Fields:    Translation:Humans
    75. Erstad DJ, Blum M, Estrella JS, Das P, Minsky BD, Ajani JA, Mansfield PF, Ikoma N, Badgwell BD. Benchmarks for nodal yield and ratio for node-positive gastric cancer. Surgery. 2021 10; 170(4):1231-1239. PMID: 34059344.
      Citations: 2     Fields:    Translation:Humans
    76. CheckMate 577 Investigators, Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Li?vre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, Schenker M, Kocon P, Zhang J, Zhu L, Lei M, Singh P, Kondo K, Cleary JM, Moehler M. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med. 2021 04 01; 384(13):1191-1203. PMID: 33789008.
      Citations: 111     Fields:    Translation:HumansCTClinical Trials
    77. Harada K, Hwang H, Wang X, Abdelhakeem A, Iwatsuki M, Blum Murphy MA, Maru DM, Weston B, Lee JH, Rogers JE, Thomas I, Shanbhag N, Zhao M, Bhutani MS, Nguyen QN, Swisher SG, Ikoma N, Badgwell BD, Hofstetter WL, Ajani JA. Frequency and Implications of Paratracheal Lymph Node Metastases in Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. Ann Surg. 2021 04 01; 273(4):751-757. PMID: 31188215.
      Citations: 1     Fields:    Translation:Humans
    78. Dong X, Song S, Li Y, Fan Y, Wang L, Wang R, Huo L, Scott A, Xu Y, Pizzi MP, Ma L, Wang Y, Jin J, Zhao W, Yao X, Johnson RL, Wang L, Wang Z, Peng G, Ajani JA. Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma-rationale for targeting ARID1A deficiency. Gut. 2022 03; 71(3):467-478. PMID: 33785559; PMCID: PMC9724309.
      Citations: 1     Fields:    Translation:AnimalsCells
    79. Xu Y, Li Y, Jin J, Han G, Sun C, Pizzi MP, Huo L, Scott A, Wang Y, Ma L, Lee JH, Bhutani MS, Weston B, Vellano C, Yang L, Lin C, Kim Y, MacLeod AR, Wang L, Wang Z, Song S, Ajani JA. Correction to: LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma. Mol Cancer. 2021 Mar 25; 20(1):56. PMID: 33766033; PMCID: PMC7992986.
      Citations: 1     Fields:    
    80. Erstad DJ, Blum M, Estrella JS, Das P, Minsky BD, Ajani JA, Mansfield PF, Badgwell BD, Ikoma N. Determinants of Survival for Patients with Neoadjuvant-Treated Node-Negative Gastric Cancer. Ann Surg Oncol. 2021 Oct; 28(11):6638-6648. PMID: 33754224.
      Citations:    Fields:    Translation:Humans
    81. Chen HY, Feng LL, Li M, Ju HQ, Ding Y, Lan M, Song SM, Han WD, Yu L, Wei MB, Pang XL, He F, Liu S, Zheng J, Ma Y, Lin CY, Lan P, Huang MJ, Zou YF, Yang ZL, Wang T, Lang JY, Orangio GR, Poylin V, Ajani JA, Wang WH, Wan XB. College of American Pathologists Tumor Regression Grading System for Long-Term Outcome in Patients with Locally Advanced Rectal Cancer. Oncologist. 2021 05; 26(5):e780-e793. PMID: 33543577; PMCID: PMC8100558.
      Citations: 4     Fields:    Translation:Humans
    82. Li Y, Wang Z, Ajani JA, Song S. Drug resistance and Cancer stem cells. Cell Commun Signal. 2021 02 15; 19(1):19. PMID: 33588867; PMCID: PMC7885480.
      Citations: 19     Fields:    Translation:HumansAnimalsCells
    83. Shah MA, Starodub A, Cunningham D, Yip D, Wainberg ZA, Bendell J, Thai D, He J, Bhargava P, Ajani JA, Bodoky G. Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1). J Clin Oncol. 2021 03 20; 39(9):990-1000. PMID: 33577358; PMCID: PMC8078292.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    84. Song S, Chen Q, Li Y, Lei G, Scott A, Huo L, Li CY, Estrella JS, Correa A, Pizzi MP, Ma L, Jin J, Liu B, Wang Y, Xiao L, Hofstetter WL, Lee JH, Weston B, Bhutani M, Shanbhag N, Johnson RL, Gan B, Wei S, Ajani JA. Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma. Gut. 2021 12; 70(12):2238-2248. PMID: 33487592; PMCID: PMC9720890.
      Citations: 2     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    85. Abdelhakeem AA, Wang X, Waters RE, Patnana M, Estrella JS, Blum Murphy M, Trail AM, Lu Y, Devine CE, Ikoma N, Das P, Badgwell BD, Rogers JE, Ajani JA. Preoperatively Treated Diffuse-Type Gastric Adenocarcinoma: Glucose vs. Other Energy Sources Substantially Influence Prognosis and Therapy Response. Cancers (Basel). 2021 Jan 23; 13(3). PMID: 33498613; PMCID: PMC7866002.
      Citations:    
    86. Mehrvarz Sarshekeh A, Alshenaifi J, Roszik J, Manyam GC, Advani SM, Katkhuda R, Verma A, Lam M, Willis J, Shen JP, Morris J, Davis JS, Loree JM, Lee HM, Ajani JA, Maru DM, Overman MJ, Kopetz S. ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer. Clin Cancer Res. 2021 03 15; 27(6):1663-1670. PMID: 33414133; PMCID: PMC7956157.
      Citations: 7     Fields:    Translation:HumansCells
    87. Blumenthaler AN, Newhook TE, Ikoma N, Estrella JS, Blum Murphy M, Das P, Minsky BD, Ajani JA, Mansfield PF, Badgwell BD. Concurrent lymphovascular and perineural invasion after preoperative therapy for gastric adenocarcinoma is associated with decreased survival. J Surg Oncol. 2021 Mar; 123(4):911-922. PMID: 33400838; PMCID: PMC7906958.
      Citations: 1     Fields:    Translation:Humans
    88. Wang R, Dang M, Harada K, Han G, Wang F, Pool Pizzi M, Zhao M, Tatlonghari G, Zhang S, Hao D, Lu Y, Zhao S, Badgwell BD, Blum Murphy M, Shanbhag N, Estrella JS, Roy-Chowdhuri S, Abdelhakeem AAF, Wang Y, Peng G, Hanash S, Calin GA, Song X, Chu Y, Zhang J, Li M, Chen K, Lazar AJ, Futreal A, Song S, Ajani JA, Wang L. Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nat Med. 2021 01; 27(1):141-151. PMID: 33398161; PMCID: PMC8074162.
      Citations: 30     Fields:    Translation:HumansCells
    89. Cascinu S, Muro K, Van Cutsem E, Oh SC, Ananda S, Wainberg ZA, Ajani J, Wei R, Liepa AM, Carlesi R, Emig M, Ohtsu A, Bodoky G, Folprecht G, Girotto G, Miron MLL. Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer. Oncologist. 2021 03; 26(3):e414-e424. PMID: 33274542; PMCID: PMC7930430.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    90. Hao D, He S, Harada K, Pizzi MP, Lu Y, Guan P, Chen L, Wang R, Zhang S, Sewastjanow-Silva M, Abdelhakeem A, Shanbhag N, Bhutani M, Han G, Lee JH, Zhao S, Weston B, Blum Murphy M, Waters R, Estrella JS, Roy-Chowdhuri S, Gan Q, Lee JS, Peng G, Hanash SM, Calin GA, Song X, Zhang J, Song S, Wang L, Ajani JA. Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma. Gut. 2021 11; 70(11):2055-2065. PMID: 33334899.
      Citations: 11     Fields:    Translation:Humans
    91. Liu Y, Baba Y, Ishimoto T, Tsutsuki H, Zhang T, Nomoto D, Okadome K, Yamamura K, Harada K, Eto K, Hiyoshi Y, Iwatsuki M, Nagai Y, Iwagami S, Miyamoto Y, Yoshida N, Komohara Y, Ohmuraya M, Wang X, Ajani JA, Sawa T, Baba H. Fusobacterium nucleatum confers chemoresistance by modulating autophagy in oesophageal squamous cell carcinoma. Br J Cancer. 2021 03; 124(5):963-974. PMID: 33299132; PMCID: PMC7921654.
      Citations: 13     Fields:    Translation:HumansCells
    92. Rogers JE, Trail A, Ajani JA. Why should localized gastric adenocarcinoma patients fare poorly after adjunctive therapy compared to surgery alone? Chin Clin Oncol. 2021 Jun; 10(3):32. PMID: 33222442.
      Citations:    Fields:    Translation:Humans
    93. Davis CH, Ikoma N, Mansfield PF, Das P, Minsky BD, Blum MA, Ajani JA, Bass BL, Badgwell BD. Comparison of laparoscopy versus mini-laparotomy for jejunostomy placement in patients with gastric adenocarcinoma. Surg Endosc. 2021 12; 35(12):6577-6582. PMID: 33170336.
      Citations:    Fields:    Translation:Humans
    94. Wang L, Yang L, Wang C, Zhao W, Ju Z, Zhang W, Shen J, Peng Y, An C, Luu YT, Song S, Yap TA, Ajani JA, Mills GB, Shen X, Peng G. Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors. J Clin Invest. 2020 11 02; 130(11):5951-5966. PMID: 33016929; PMCID: PMC7598069.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    95. Zou J, Qin W, Yang L, Wang L, Wang Y, Shen J, Xiong W, Yu S, Song S, Ajani JA, Lin SY, Mills GB, Yuan X, Chen J, Peng G. Genetic alterations and expression characteristics of ARID1A impact tumor immune contexture and survival in early-onset gastric cancer. Am J Cancer Res. 2020; 10(11):3947-3972. PMID: 33294279; PMCID: PMC7716160.
      Citations: 4     
    96. Kim BJ, Chiang YJ, Das P, Minsky BD, Blum MA, Ajani JA, Estrella JS, Hofstetter WL, Tzeng CD, Badgwell BD, Mansfield PF, Ikoma N. Treatment Patterns for Gastroesophageal Junction Adenocarcinoma in the United States. J Clin Med. 2020 Oct 29; 9(11). PMID: 33138060; PMCID: PMC7692279.
      Citations: 2     
    97. Yamashita K, Iwatsuki M, Yasuda-Yoshihara N, Morinaga T, Nakao Y, Harada K, Eto K, Kurashige J, Hiyoshi Y, Ishimoto T, Nagai Y, Iwagami S, Baba Y, Miyamoto Y, Yoshida N, Ajani JA, Baba H. Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer. Br J Cancer. 2021 02; 124(3):595-603. PMID: 33100329; PMCID: PMC7851117.
      Citations: 3     Fields:    Translation:HumansCells
    98. Li Y, Song S, Pizzi MP, Han G, Scott AW, Jin J, Xu Y, Wang Y, Huo L, Ma L, Vellano C, Luo X, MacLeod R, Wang L, Wang Z, Ajani JA. LncRNA PVT1 Is a Poor Prognosticator and Can Be Targeted by PVT1 Antisense Oligos in Gastric Adenocarcinoma. Cancers (Basel). 2020 Oct 15; 12(10). PMID: 33076512; PMCID: PMC7602573.
      Citations: 4     
    99. Yao X, Ajani JA, Song S. Molecular biology and immunology of gastric cancer peritoneal metastasis. Transl Gastroenterol Hepatol. 2020; 5:57. PMID: 33073052; PMCID: PMC7530317.
      Citations: 4     
    100. Harada K, Rogers JE, Iwatsuki M, Yamashita K, Baba H, Ajani JA. Recent advances in treating oesophageal cancer. F1000Res. 2020; 9. PMID: 33042518; PMCID: PMC7531047.
      Citations: 7     Fields:    Translation:Humans
    101. Abdelhakeem A, Wang X, Rogers JE, Trail A, Zhao M, Blum-Murphy M, Estrella JS, Ajani JA. Outcomes of Advanced Gastroesophageal Cancer Patients with Equivocal HER2 Expression with or without ERBB2 Gene Amplification. Oncology. 2020; 98(12):884-888. PMID: 32998149.
      Citations:    Fields:    Translation:Humans
    102. Stark AP, Blum MM, Chiang YJ, Das P, Minsky BD, Estrella JS, Ajani JA, Badgwell BD, Mansfield P, Ikoma N. Preoperative Therapy Regimen Influences the Incidence and Implication of Nodal Downstaging in Patients with Gastric Cancer. J Gastric Cancer. 2020 Sep; 20(3):313-327. PMID: 33024587; PMCID: PMC7521984.
      Citations: 2     
    103. He F, Yu L, Ding Y, Li ZH, Wang J, Zheng J, Chen HY, Liu S, Pang XL, Ajani JA, Wan XB. Effects of neoadjuvant chemotherapy with or without intensity-modulated radiotherapy for patients with rectal cancer. Cancer Sci. 2020 Nov; 111(11):4205-4217. PMID: 32860448; PMCID: PMC7648035.
      Citations: 2     Fields:    Translation:Humans
    104. Corsini EM, Foo WC, Mitchell KG, Zhou N, Maru DM, Ajani JA, Hofstetter WL, Esophageal Adenocarcinoma Working Group, Correa AM, Antonoff MB, Lin SH, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL. Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy. J Thorac Cardiovasc Surg. 2021 Nov; 162(5):1404-1412.e2. PMID: 33010880.
      Citations: 2     Fields:    Translation:Humans
    105. Corsini EM, Mitchell KG, Zhou N, Antonoff MB, Mehran RJ, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Maru DM, Lin SH, Ajani JA, Hofstetter WL. Modified En Bloc Esophagectomy Compared With Standard Resection After Neoadjuvant Chemoradiation. Ann Thorac Surg. 2021 04; 111(4):1133-1140. PMID: 32857997.
      Citations:    Fields:    Translation:Humans
    106. Blumenthaler AN, Ikoma N, Blum M, Das P, Minsky BD, Mansfield PF, Ajani JA, Badgwell BD. Relationship between initial management strategy and survival in patients with gastric outlet obstruction due to gastric cancer. J Surg Oncol. 2020 Dec; 122(7):1373-1382. PMID: 32810292; PMCID: PMC7722201.
      Citations: 1     Fields:    Translation:Humans
    107. Chen B, Dragomir MP, Fabris L, Bayraktar R, Liu X, Tang C, Li Y, Shimura T, Ivkovic TC, De Los Santos MC, Anfossi S, Shimizu M, Shah MY, Ling H, Shen P, Multani AS, Pardini B, Burks JK, Katayama H, Reineke LC, Huo L, Syed M, Song S, Ferracin M, Oki E, Fromm B, Ivan C, Bhuvaneshwar K, Gusev Y, Mimori K, Menter D, Sen S, Matsuyama T, Uetake H, Vasilescu C, Kopetz S, Parker-Thornburg J, Taguchi A, Hanash SM, Girnita L, Slaby O, Goel A, Varani G, Gagea M, Li C, Ajani JA, Calin GA, Knutsen E. The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. Gastroenterology. 2020 12; 159(6):2146-2162.e33. PMID: 32805281; PMCID: PMC7725986.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    108. Harada K, Wu CC, Wang X, Mizrak Kaya D, Amlashi FG, Iwatsuki M, Blum Murphy MA, Maru DM, Weston B, Lee JH, Rogers JE, Thomas I, Shanbhag N, Bhutani MS, Hofstetter WL, Nguyen QN, Ajani JA. Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation. Ann Surg. 2020 08; 272(2):311-318. PMID: 32675544.
      Citations: 5     Fields:    Translation:HumansCells
    109. Blumenthaler AN, Allen CJ, Ikoma N, Blum M, Das P, Minsky BD, Mansfield PF, Ajani JA, Badgwell BD. Laparoscopic HIPEC for Low-Volume Peritoneal Metastasis in Gastric and Gastroesophageal Adenocarcinoma. Ann Surg Oncol. 2020 Dec; 27(13):5047-5056. PMID: 32737700; PMCID: PMC7682939.
      Citations: 5     Fields:    Translation:Humans
    110. He F, Ju HQ, Ding Y, Jiang Z, Li Z, Huang B, Wang X, Zhao Y, Li Y, Qi B, Luo W, Zhang Z, Pei Q, Chen H, Liu S, Pang X, Zheng J, Wang J, Ajani JA, Wan XB. Association between adjuvant chemotherapy and survival in patients with rectal cancer and pathological complete response after neoadjuvant chemoradiotherapy and resection. Br J Cancer. 2020 10; 123(8):1244-1252. PMID: 32724220; PMCID: PMC7553967.
      Citations: 3     Fields:    Translation:Humans
    111. Allen CJ, Blumenthaler AN, Smith GL, Das P, Minsky BD, Blum M, Ajani J, Mansfield PF, Ikoma N, Badgwell BD. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Preoperative Therapy for Resectable Gastric Adenocarcinoma: A Propensity Score-Matched Analysis of a Large, Single-Institution Experience. Ann Surg Oncol. 2021 Feb; 28(2):758-765. PMID: 32696305; PMCID: PMC7855908.
      Citations: 2     Fields:    Translation:Humans
    112. White MG, Kothari A, Ikoma N, Murphy MB, Song S, Ajani J, Mansfield P, Badgwell B. Factors Associated with Resection and Survival After Laparoscopic HIPEC for Peritoneal Gastric Cancer Metastasis. Ann Surg Oncol. 2020 Dec; 27(13):4963-4969. PMID: 32648181; PMCID: PMC8601118.
      Citations: 2     Fields:    Translation:Humans
    113. Uchihara T, Miyake K, Yonemura A, Komohara Y, Itoyama R, Koiwa M, Yasuda T, Arima K, Harada K, Eto K, Hayashi H, Iwatsuki M, Iwagami S, Baba Y, Yoshida N, Yashiro M, Masuda M, Ajani JA, Tan P, Baba H, Ishimoto T. Extracellular Vesicles from Cancer-Associated Fibroblasts Containing Annexin A6 Induces FAK-YAP Activation by Stabilizing ?1 Integrin, Enhancing Drug Resistance. Cancer Res. 2020 08 15; 80(16):3222-3235. PMID: 32605995.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    114. Harada K, Zhao M, Shanbhag N, Baba H, Ajani JA. Palliative care for advanced gastric cancer. Expert Rev Anticancer Ther. 2020 07; 20(7):575-580. PMID: 32543938; PMCID: PMC7415645.
      Citations: 3     Fields:    Translation:Humans
    115. Rogers JE, Ajani JA. The role of ramucirumab and pembrolizumab combination in patients with advanced non-small cell lung cancer, gastroesophageal adenocarcinoma, or urothelial carcinoma. Chin Clin Oncol. 2021 Jun; 10(3):30. PMID: 32576019.
      Citations:    Fields:    Translation:Humans
    116. Badgwell B, Ikoma N, Murphy MB, Wang X, Estrella J, Roy-Chowdhuri S, Das P, Minsky BD, Lano E, Song S, Mansfield P, Ajani J. A Phase II Trial of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Perfusion with Chemotherapy for Patients with Gastric Cancer and Carcinomatosis or Positive Cytology. Ann Surg Oncol. 2021 Jan; 28(1):258-264. PMID: 32556731.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    117. Ikoma N, Estrella JS, Blum Murphy M, Das P, Minsky BD, Mansfield P, Ajani JA, Badgwell BD. Tumor Regression Grade in Gastric Cancer After Preoperative Therapy. J Gastrointest Surg. 2021 06; 25(6):1380-1387. PMID: 32542556.
      Citations: 5     Fields:    Translation:Humans
    118. Yamashita K, Iwatsuki M, Ajani JA, Baba H. Programmed death ligand-1 expression in gastrointestinal cancer: Clinical significance and future challenges. Ann Gastroenterol Surg. 2020 Jul; 4(4):369-378. PMID: 32724880; PMCID: PMC7382440.
      Citations: 2     
    119. Seriak D, Menshikova S, Vakhabova Y, Ajani JA, Ignatova E, Fedyanin M, Tryakin A, Pokataev I, Smirnova K, Tjulandin S. Epstein-Barr virus-associated gastric cancer: disease that requires special approach. Gastric Cancer. 2020 11; 23(6):951-960. PMID: 32514646.
      Citations: 11     Fields:    Translation:HumansCells
    120. Stark AP, Estrella JS, Chiang YJ, Das P, Minsky BD, Blum Murphy MA, Ajani JA, Mansfield P, Badgwell BD, Ikoma N. Impact of tumor regression grade on recurrence after preoperative chemoradiation and gastrectomy for gastric cancer. J Surg Oncol. 2020 Sep; 122(3):422-432. PMID: 32462681; PMCID: PMC7731155.
      Citations: 2     Fields:    Translation:Humans
    121. Mizrak Kaya D, Harada K, Blum Murphy MA, Lee JH, Bhutani MS, Weston B, Thomas I, Rogers JE, Das P, Badgwell BD, Ajani JA, Nogueras Gonz?lez GM. Efficacy of Three-Drug Induction Chemotherapy Followed by Preoperative Chemoradiation in Patients with Localized Gastric Adenocarcinoma. Oncology. 2020; 98(8):542-548. PMID: 32434189.
      Citations: 2     Fields:    Translation:Humans
    122. Harada K, Patnana M, Wang X, Iwatsuki M, Murphy MAB, Zhao M, Das P, Minsky BD, Weston B, Lee JH, Bhutani MS, Estrella JS, Shanbhag N, Ikoma N, Badgwell BD, Ajani JA. Low metabolic activity in primary gastric adenocarcinoma is associated with resistance to chemoradiation and the presence of signet ring cells. Surg Today. 2020 Oct; 50(10):1223-1231. PMID: 32409870; PMCID: PMC9396945.
      Citations:    Fields:    Translation:HumansCells
    123. Ajani JA, Javle M, Eng C, Fogelman D, Smith J, Anderson B, Zhang C, Iizuka K. Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumors. Invest New Drugs. 2020 12; 38(6):1763-1773. PMID: 32377978; PMCID: PMC7575509.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    124. Harada K, Hwang H, Wang X, Abdelhakeem A, Iwatsuki M, Murphy MAB, Maru DM, Weston B, Lee JH, Rogers JE, Trail A, Shanbhag N, Zhao M, Bhutani MS, Nguyen QN, Swisher SG, Ikoma N, Das P, Hofstetter WL, Badgwell BD, Ajani JA. Brain metastases in patients with upper gastrointestinal cancer is associated with proximally located adenocarcinoma and lymph node metastases. Gastric Cancer. 2020 09; 23(5):904-912. PMID: 32347396; PMCID: PMC7442686.
      Citations: 3     Fields:    Translation:Humans
    125. Ajani JA, Xu Y, Huo L, Wang R, Li Y, Wang Y, Pizzi MP, Scott A, Harada K, Ma L, Yao X, Jin J, Zhao W, Dong X, Badgwell BD, Shanbhag N, Tatlonghari G, Estrella JS, Roy-Chowdhuri S, Kobayashi M, Vykoukal JV, Hanash SM, Calin GA, Peng G, Lee JS, Johnson RL, Wang Z, Wang L, Song S. YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition. Gut. 2021 01; 70(1):55-66. PMID: 32345613.
      Citations: 14     Fields:    Translation:HumansAnimals
    126. Zafar SN, Blum M, Chiang YJ, Ajani JA, Estrella JS, Das P, Minsky BD, Hofstetter WL, Mansfield P, Badgwell BD, Ikoma N. Preoperative Chemoradiation Versus Chemotherapy in Gastroesophageal Junction Adenocarcinoma. Ann Thorac Surg. 2020 08; 110(2):398-405. PMID: 32289300.
      Citations: 6     Fields:    Translation:Humans
    127. Song S, Li Y, Xu Y, Ma L, Pool Pizzi M, Jin J, Scott AW, Huo L, Wang Y, Lee JH, Bhutani MS, Weston B, Shanbhag ND, Johnson RL, Ajani JA. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma. Mol Oncol. 2020 06; 14(6):1410-1426. PMID: 32175692; PMCID: PMC7266288.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    128. Duleba M, Yamamoto Y, Neupane R, Rao W, Xie J, Qi Y, Liew AA, Niroula S, Zhang Y, Mahalingam R, Wang S, Goller K, Ajani JA, Vincent M, Ho KY, Hou JK, Hyams JS, Sylvester FA, Crum CP, McKeon F, Xian W. Cloning of ground-state intestinal stem cells from endoscopic biopsy samples. Nat Protoc. 2020 05; 15(5):1612-1627. PMID: 32238950.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    129. Lu Y, Wang L, Ajani JA. Rare Esophageal Leptomeningeal Metastases Detected on 18F-FDG PET/CT. Clin Nucl Med. 2020 Apr; 45(4):334-335. PMID: 31977493.
      Citations:    Fields:    Translation:Humans
    130. Schizas D, Charalampakis N, Kole C, Mylonas KS, Katsaros I, Psyrri A, Karamouzis MV, Liakakos T, Zhao M, Ajani JA. Immunotherapy for esophageal cancer: a 2019 update. Immunotherapy. 2020 02; 12(3):203-218. PMID: 32208794.
      Citations: 9     Fields:    Translation:HumansCells
    131. Mitchell KG, Nelson DB, Corsini EM, Vaporciyan AA, Antonoff MB, Mehran RJ, Rice DC, Roth JA, Sepesi B, Walsh GL, Bhutani MS, Maru DM, Wu CC, Nguyen QN, Ajani JA, Swisher SG, Hofstetter WL. Morbidity following salvage esophagectomy for squamous cell carcinoma: the MD Anderson experience. Dis Esophagus. 2020 Mar 16; 33(3). PMID: 31313820.
      Citations: 3     Fields:    Translation:Humans
    132. Lin SH, Hobbs BP, Verma V, Tidwell RS, Smith GL, Lei X, Corsini EM, Mok I, Wei X, Yao L, Wang X, Komaki RU, Chang JY, Chun SG, Jeter MD, Swisher SG, Ajani JA, Blum-Murphy M, Vaporciyan AA, Mehran RJ, Koong AC, Gandhi SJ, Hofstetter WL, Hong TS, Delaney TF, Liao Z, Mohan R. Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. J Clin Oncol. 2020 05 10; 38(14):1569-1579. PMID: 32160096; PMCID: PMC7213588.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    133. Rogers JE, Xiao L, Trail A, Blum Murphy M, Palmer M, Ajani JA. Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer. Oncology. 2020; 98(5):289-294. PMID: 32097933.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    134. Allen CJ, Blumenthaler AN, Das P, Minsky BD, Blum M, Roy-Chowdhuri S, Ajani JA, Ikoma N, Mansfield PF, Badgwell BD. Staging laparoscopy and peritoneal cytology in patients with early stage gastric adenocarcinoma. World J Surg Oncol. 2020 Feb 17; 18(1):39. PMID: 32066454; PMCID: PMC7026970.
      Citations: 5     Fields:    Translation:Humans
    135. Jin J, Xu Y, Huo L, Ma L, Scott AW, Pizzi MP, Li Y, Wang Y, Yao X, Song S, Ajani JA. An improved strategy for CRISPR/Cas9 gene knockout and subsequent wildtype and mutant gene rescue. PLoS One. 2020; 15(2):e0228910. PMID: 32053639; PMCID: PMC7018052.
      Citations: 5     Fields:    Translation:HumansCells
    136. Dragomir MP, Kopetz S, Ajani JA, Calin GA. Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility. Gut. 2020 04; 69(4):748-763. PMID: 32034004.
      Citations: 69     Fields:    Translation:Humans
    137. Lopez A, Harada K, Chen HC, Bhutani MS, Weston B, Lee JH, Maru DM, Chin FW, Rogers JE, Thomas I, Amlashi FG, Blum-Murphy MA, Rice DC, Zhao M, Hofstetter WL, Nguyen Q, Ajani JA. Taxane-based or platinum-based combination chemotherapy given concurrently with radiation followed by surgery resulting in high cure rates in esophageal cancer patients. Medicine (Baltimore). 2020 Feb; 99(9):e19295. PMID: 32118743; PMCID: PMC7478597.
      Citations: 1     Fields:    Translation:Humans
    138. Van Cutsem E, Muro K, Cunningham D, Sobrero A, Ajani J, Oh SC, Al-Batran SE, Wainberg ZA, Wijayawardana SR, Melemed S, Ferry D, Hozak RR, Ohtsu A, RAINBOW Investigators, Bodoky G, Cascinu S. Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study. Eur J Cancer. 2020 03; 127:150-157. PMID: 32014812.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    139. Blum Murphy M, Ikoma N, Wang X, Estrella J, Roy-Chowdhuri S, Das P, Minsky BD, Song S, Mansfield P, Ajani J, Badgwell B. Phase I Trial of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) with Cisplatin, Mitomycin, and Paclitaxel in Patients with Gastric Adenocarcinoma and Associated Carcinomatosis or Positive Cytology. Ann Surg Oncol. 2020 Aug; 27(8):2806-2811. PMID: 31974712.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    140. Lei G, Zhang Y, Koppula P, Liu X, Zhang J, Lin SH, Ajani JA, Xiao Q, Liao Z, Wang H, Gan B. The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. Cell Res. 2020 02; 30(2):146-162. PMID: 31949285; PMCID: PMC7015061.
      Citations: 166     Fields:    Translation:HumansAnimalsCells
    141. Veeranki OL, Tong Z, Mejia A, Verma A, Katkhuda R, Bassett R, Kim TB, Wang J, Lang W, Mino B, Solis L, Kingsley C, Norton W, Tailor R, Wu JY, Krishnan S, Lin SH, Blum M, Hofstetter W, Ajani J, Kopetz S, Maru D. A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries. Dis Model Mech. 2019 12 17; 12(12). PMID: 31732509; PMCID: PMC6918774.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    142. Song S, Wang Z, Li Y, Ma L, Jin J, Scott AW, Xu Y, Estrella JS, Song Y, Liu B, Johnson RL, Ajani JA. PPARd Interacts with the Hippo Coactivator YAP1 to Promote SOX9 Expression and Gastric Cancer Progression. Mol Cancer Res. 2020 03; 18(3):390-402. PMID: 31796534.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    143. Moningi S, Ajani JA, Badgwell BD, Murphy MB, Ikoma N, Mansfield PF, Ho JC, Suh Y, Crane C, Herman JM, Holliday EB, Koay E, Koong AC, Krishnan S, Minsky B, Smith G, Taniguchi C, Das P. IMRT Reduces Acute Toxicity in Patients Treated With Preoperative Chemoradiation for Gastric Cancer. Adv Radiat Oncol. 2020 May-Jun; 5(3):369-376. PMID: 32529130; PMCID: PMC7276694.
      Citations: 3     
    144. Xu Y, Song S, Wang Z, Ajani JA. The role of hedgehog signaling in gastric cancer: molecular mechanisms, clinical potential, and perspective. Cell Commun Signal. 2019 11 27; 17(1):157. PMID: 31775795; PMCID: PMC6882007.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    145. Ikoma N, Agnes A, Chen HC, Wang X, Blum MM, Das P, Minsky B, Estrella JS, Mansfield P, Ajani JA, Badgwell BD. Linitis Plastica: a Distinct Type of Gastric Cancer. J Gastrointest Surg. 2020 05; 24(5):1018-1025. PMID: 31754987.
      Citations: 7     Fields:    Translation:Humans
    146. Chen D, Menon H, Verma V, Seyedin SN, Ajani JA, Hofstetter WL, Nguyen QN, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Barsoumian HB, Erasmus JJ, Lee JH, Bhutani MS, Hess KR, Minsky BD, Welsh JW. Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer. JAMA Oncol. 2019 11 01; 5(11):1597-1604. PMID: 31529018; PMCID: PMC6749545.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    147. Dumbrava EEI, Balaji K, Raghav K, Hess K, Javle M, Blum-Murphy M, Ajani J, Kopetz S, Broaddus R, Routbort M, Demirhan M, Zheng X, Pant S, Tsimberidou AM, Subbiah V, Hong DS, Rodon J, Shaw KM, Piha-Paul SA, Meric-Bernstam F. Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. JCO Precis Oncol. 2019; 3. PMID: 32923865; PMCID: PMC7446516.
      Citations: 4     Fields:    
    148. Ahmed O, Ajani JA, Lee JH. Endoscopic management of esophageal cancer. World J Gastrointest Oncol. 2019 Oct 15; 11(10):830-841. PMID: 31662822; PMCID: PMC6815921.
      Citations: 7     
    149. Allen CJ, Newhook TE, Vreeland TJ, Das P, Minsky BD, Blum M, Song S, Ajani J, Ikoma N, Mansfield PF, Roy-Chowdhuri S, Badgwell BD. Yield of peritoneal cytology in staging patients with gastric and gastroesophageal cancer. J Surg Oncol. 2019 Dec; 120(8):1350-1357. PMID: 31612494.
      Citations: 4     Fields:    Translation:Humans
    150. Xu Y, Li Y, Jin J, Han G, Sun C, Pizzi MP, Huo L, Scott A, Wang Y, Ma L, Lee JH, Bhutani MS, Weston B, Vellano C, Yang L, Lin C, Kim Y, MacLeod AR, Wang L, Wang Z, Song S, Ajani JA. LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma. Mol Cancer. 2019 10 10; 18(1):141. PMID: 31601234; PMCID: PMC6785865.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    151. Rivin Del Campo E, Matzinger O, Haustermans K, Glynne-Jones R, Winter KA, Konski AA, Ajani JA, Hannoun-Levi JM, Chakravarthy AB, Meadows H, Northover J, Collette L, Christiaens M, Peiffert D, Bosset JF, Puyraveau M, Maingon P. Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC). Eur J Cancer. 2019 11; 121:130-143. PMID: 31574418; PMCID: PMC6924923.
      Citations: 2     Fields:    Translation:Humans
    152. Allen CJ, Vreeland TJ, Newhook TE, Das P, Minsky BD, Blum M, Ajani J, Ikoma N, Mansfield PF, Badgwell BD. Prognostic Value of Lymph Node Yield After Neoadjuvant Chemoradiation for Gastric Cancer. Ann Surg Oncol. 2020 Feb; 27(2):534-542. PMID: 31552618.
      Citations: 2     Fields:    Translation:Humans
    153. Wang L, Ajani JA. Ushering in Liquid Biopsy for the Microsatellite Status: Advantages and Caveats. Clin Cancer Res. 2019 12 01; 25(23):6887-6889. PMID: 31527165.
      Citations: 6     Fields:    Translation:HumansCells
    154. Sonoda K, Samdani RT, Ikoma N, Kaya DM, Blum-Murphy M, Ajani JA, Badgwell BD, Katz MH, Rashid A, Estrella JS. Gastric cancer in the remnant stomach after pancreaticoduodenectomy: A case series. J Surg Oncol. 2019 Dec; 120(7):1137-1141. PMID: 31498442.
      Citations: 1     Fields:    Translation:Humans
    155. Rogers JE, Ajani JA. Taxane- Versus Cisplatin-Based Chemotherapy With Radiation Therapy Is a Better Platform to Refine Esophageal Cancer Therapy. J Clin Oncol. 2019 10 20; 37(30):2805-2806. PMID: 31465257.
      Citations: 2     Fields:    Translation:Humans
    156. Yamashita K, Iwatsuki M, Harada K, Eto K, Hiyoshi Y, Ishimoto T, Nagai Y, Iwagami S, Miyamoto Y, Yoshida N, Komohara Y, Ajani JA, Baba H. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer. Gastric Cancer. 2020 01; 23(1):95-104. PMID: 31451991.
      Citations: 23     Fields:    Translation:HumansCells
    157. Stark AP, Ikoma N, Chiang YJ, Estrella JS, Das P, Minsky BD, Blum MM, Ajani JA, Mansfield P, Badgwell BD. Characteristics and Survival of Gastric Cancer Patients with Pathologic Complete Response to Preoperative Therapy. Ann Surg Oncol. 2019 Oct; 26(11):3602-3610. PMID: 31350645.
      Citations: 8     Fields:    Translation:Humans
    158. Tong Z, Mejia A, Veeranki O, Verma A, Correa AM, Dokey R, Patel V, Solis LM, Mino B, Kathkuda R, Rodriguez-Canales J, Lin SH, Krishnan S, Kopetz S, Blum M, Ajani JA, Hofstetter WL, Maru DM. Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma. Ther Adv Med Oncol. 2019; 11:1758835919864850. PMID: 31384313; PMCID: PMC6659187.
      Citations: 6     
    159. Veeranki OL, Tong Z, Dokey R, Mejia A, Zhang J, Qiao Y, Singh PK, Katkhuda R, Mino B, Tailor R, Canales JR, Bassett R, Ajani J, Wu JY, Kopetz S, Blum M, Hofstetter W, Tetzlaff M, Krishnan S, Lin SH, Maru D. Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma. Oncotarget. 2019 Jul 23; 10(45):4703-4718. PMID: 31384397; PMCID: PMC6659793.
      Citations: 4     Fields:    
    160. Yamashita K, Iwatsuki M, Harada K, Koga Y, Kiyozumi Y, Eto K, Hiyoshi Y, Ishimoto T, Iwagami S, Baba Y, Miyamoto Y, Yoshida N, Komohara Y, Ajani JA, Baba H. Can PD-L1 expression evaluated by biopsy sample accurately reflect its expression in the whole tumour in gastric cancer? Br J Cancer. 2019 07; 121(3):278-280. PMID: 31285589; PMCID: PMC6738080.
      Citations: 4     Fields:    Translation:Humans
    161. Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Corvera C, Das P, Denlinger CS, Enzinger PC, Fanta P, Farjah F, Gerdes H, Gibson M, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Johung KL, Keswani RN, Kleinberg LR, Leong S, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Paluri RK, Park H, Perry KA, Pimiento J, Poultsides GA, Roses R, Strong VE, Wiesner G, Willett CG, Wright CD, McMillian NR, Pluchino LA. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 07 01; 17(7):855-883. PMID: 31319389.
      Citations: 179     Fields:    Translation:Humans
    162. Takeuchi M, Ajani JA, Fang X, Pfeiffer P, Takeuchi M, van Laarhoven HWM. Meta-Enrichment Analyses to Identify Advanced Gastric Cancer Patients Who Achieve a Higher Response to S-1/Cisplatin. Cancers (Basel). 2019 06 21; 11(6). PMID: 31234436; PMCID: PMC6627221.
      Citations:    
    163. Wang R, Song S, Harada K, Ghazanfari Amlashi F, Badgwell B, Pizzi MP, Xu Y, Zhao W, Dong X, Jin J, Wang Y, Scott A, Ma L, Huo L, Vicente D, Blum Murphy M, Shanbhag N, Tatlonghari G, Thomas I, Rogers J, Kobayashi M, Vykoukal J, Estrella JS, Roy-Chowdhuri S, Han G, Zhang S, Mao X, Song X, Zhang J, Gu J, Johnson RL, Calin GA, Peng G, Lee JS, Hanash SM, Futreal A, Wang Z, Wang L, Ajani JA. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut. 2020 01; 69(1):18-31. PMID: 31171626; PMCID: PMC6943252.
      Citations: 29     Fields:    Translation:Humans
    164. Yin Y, Liu W, Shen Q, Zhang P, Wang L, Tao R, Li H, Ma X, Zeng X, Cheong JH, Song S, Ajani JA, Mills GB, Tao K, Peng G. The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer. Mol Cancer Ther. 2019 08; 18(8):1439-1450. PMID: 31142662; PMCID: PMC8345820.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    165. Harada K, Zhao M, Baba H, Ajani JA. Endoscopic resection for esophageal or gastroesophageal junction adenocarcinoma. Dig Med Res. 2019 Apr; 2. PMID: 31179442; PMCID: PMC6553865.
      Citations:    
    166. Rogers JE, Xiao L, Amlashi FG, Elimova E, Blum Murphy MA, Sanders E, Shanbhag N, Thomas I, Ajani JA. Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma. Oncology. 2019; 96(5):252-258. PMID: 30893708.
      Citations: 4     Fields:    Translation:Humans
    167. Koga Y, Iwatsuki M, Yamashita K, Kiyozumi Y, Kurashige J, Masuda T, Eto K, Iwagami S, Harada K, Ishimoto T, Baba Y, Yoshida N, Miyanari N, Takamori H, Ajani JA, Baba H. The role of FBXW7, a cell-cycle regulator, as a predictive marker of recurrence of gastrointestinal stromal tumors. Gastric Cancer. 2019 11; 22(6):1100-1108. PMID: 30854619.
      Citations: 1     Fields:    Translation:HumansCells
    168. Abu-Hanna A, Ter Veer E, van Kleef JJ, Lordick F, Stahl M, Ajani JA, Guimbaud R, Park SH, Dutton SJ, Bang YJ, Boku N, Mohammad NH, Sprangers MAG, Verhoeven RHA, Zwinderman AH, van Oijen MGH, van Laarhoven HWM, van den Boorn HG. SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer. Cancers (Basel). 2019 Feb 05; 11(2). PMID: 30764578; PMCID: PMC6406639.
      Citations: 8     
    169. Shah MA, Kang YK, Ohtsu A, Ajani JA, Van Cutsem E, Hoersch S, Harle-Yge ML, de Haas SL, Thuss-Patience PC. Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer. Gastric Cancer. 2019 07; 22(4):803-816. PMID: 30706247.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    170. Newhook TE, Agnes A, Blum M, Estrella JS, Das P, Ho L, Ajani JA, Minsky BD, Mansfield P, Badgwell BD. Laparoscopic Hyperthermic Intraperitoneal Chemotherapy is Safe for Patients with Peritoneal Metastases from Gastric Cancer and May Lead to Gastrectomy. Ann Surg Oncol. 2019 May; 26(5):1394-1400. PMID: 30680477.
      Citations: 10     Fields:    Translation:Humans
    171. Lopez A, Harada K, Vasilakopoulou M, Shanbhag N, Ajani JA. Targeting Angiogenesis in Colorectal Carcinoma. Drugs. 2019 Jan; 79(1):63-74. PMID: 30617958.
      Citations: 18     Fields:    Translation:Humans
    172. Harada K, Abdelhakeem AAF, Ajani JA. A balancing act: dual immune-checkpoint inhibition for oesophagogastric cancer. Nat Rev Clin Oncol. 2019 01; 16(1):9-10. PMID: 30291292.
      Citations: 2     Fields:    Translation:Humans
    173. Bang YJ, Kang YK, Ng M, Chung HC, Wainberg ZA, Gendreau S, Chan WY, Xu N, Maslyar D, Meng R, Chau I, Ajani JA. A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer. Eur J Cancer. 2019 02; 108:17-24. PMID: 30592991.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    174. Iwatsuki M, Harada K, Baba H, Ajani JA. Higher rate of colon polyp detection aided by an artificial intelligent software. Transl Gastroenterol Hepatol. 2018; 3:106. PMID: 30701213; PMCID: PMC6327163.
      Citations: 1     
    175. Li F, Xu Y, Liu B, Singh PK, Zhao W, Jin J, Han G, Scott AW, Dong X, Huo L, Ma L, Pizzi MP, Wang Y, Li Y, Harada K, Xie M, Skinner HD, Ding S, Wang L, Krishnan S, Johnson RL, Song S, Ajani JA. YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer. Clin Cancer Res. 2019 04 01; 25(7):2264-2277. PMID: 30563933.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    176. Morlock R, Maeda H, Ajani J, Casamayor M. Targeted literature review of the global burden of gastric cancer. Ecancermedicalscience. 2018; 12:883. PMID: 30679950; PMCID: PMC6345079.
      Citations: 24     
    177. Harada K, Pool Pizzi M, Baba H, Shanbhag ND, Song S, Ajani JA. Cancer stem cells in esophageal cancer and response to therapy. Cancer. 2018 10 15; 124(20):3962-3964. PMID: 30368777; PMCID: PMC6234092.
      Citations: 4     Fields:    Translation:HumansCells
    178. Iwatsuki M, Harada K, Iwagami S, Eto K, Ishimoto T, Baba Y, Yoshida N, Ajani JA, Baba H. Neoadjuvant and adjuvant therapy for gastrointestinal stromal tumors. Ann Gastroenterol Surg. 2019 Jan; 3(1):43-49. PMID: 30697609; PMCID: PMC6345649.
      Citations: 7     
    179. Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L, Cancer Genome Atlas Research Network, Weinstein JN, Mishra L, Akbani R. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-? Superfamily. Cell Syst. 2018 10 24; 7(4):422-437.e7. PMID: 30268436; PMCID: PMC6370347.
      Citations: 63     Fields:    Translation:HumansCells
    180. Gu J, Zhang J, Zheng L, Ajani JA, Wu X, Ye Y. Serum miR-331-3p predicts tumor recurrence in esophageal adenocarcinoma. Sci Rep. 2018 09 18; 8(1):14006. PMID: 30228315; PMCID: PMC6143616.
      Citations: 11     Fields:    Translation:Humans
    181. Ajani JA, Bhutani MS, Swisher SG. Oesophageal preservation in locally advanced oesophageal cancer. Lancet Oncol. 2018 09; 19(9):e430. PMID: 30191840.
      Citations: 1     Fields:    Translation:Humans
    182. Harada K, Lopez A, Shanbhag N, Badgwell B, Baba H, Ajani J. Recent advances in the management of gastric adenocarcinoma patients. F1000Res. 2018; 7. PMID: 30228868; PMCID: PMC6117861.
      Citations: 10     Fields:    Translation:Humans
    183. Harada K, Song S, Ajani JA. Attenuation of YAP1 can potentially target cancer stem cells to overcome drug resistance. Oncoscience. 2018 Jul; 5(7-8):214-215. PMID: 30234141; PMCID: PMC6142898.
      Citations:    
    184. Song S, Ajani JA. Reply. Gastroenterology. 2018 09; 155(3):934-935. PMID: 30098926.
      Citations:    Fields:    
    185. Xi M, Hallemeier CL, Merrell KW, Liao Z, Murphy MAB, Ho L, Hofstetter WL, Mehran R, Lee JH, Bhutani MS, Weston B, Maru DM, Komaki R, Ajani JA, Lin SH. Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma. Ann Surg. 2018 08; 268(2):289-295. PMID: 28628563.
      Citations: 6     Fields:    Translation:Humans
    186. Ikoma N, Estrella JS, Hofstetter WL, Ajani JA, Fournier KF, Mansfield PF, Skibber JM, Badgwell BD. Surgeon Assessment of Gastric Cancer Lymph Node Specimens with a Video of Technique. J Gastrointest Surg. 2018 11; 22(11):2013-2019. PMID: 30054780.
      Citations: 2     Fields:    Translation:Humans
    187. Vicente D, Ikoma N, Chiang YJ, Fournier K, Tzeng CD, Song S, Mansfield P, Ajani J, Badgwell BD. Preoperative Therapy for Gastric Adenocarcinoma is Protective for Poor Oncologic Outcomes in Patients with Complications After Gastrectomy. Ann Surg Oncol. 2018 Sep; 25(9):2720-2730. PMID: 29987602.
      Citations: 10     Fields:    Translation:Humans
    188. Ikoma N, Hofstetter WL, Estrella JS, Das P, Minsky BD, Fournier KF, Mansfield PF, Ajani JA, Badgwell BD. The ypT category does not impact overall survival in node negative gastric cancer. J Surg Oncol. 2018 Jun; 117(8):1721-1728. PMID: 29949666; PMCID: PMC7703861.
      Citations: 5     Fields:    Translation:Humans
    189. Thiels CA, Ikoma N, Fournier K, Das P, Blum M, Estrella JS, Minsky BD, Ajani J, Mansfield P, Badgwell BD. Repeat staging laparoscopy for gastric cancer after preoperative therapy. J Surg Oncol. 2018 Jul; 118(1):61-67. PMID: 29878364; PMCID: PMC7703853.
      Citations: 6     Fields:    Translation:Humans
    190. Mizrak Kaya D, Harada K, Amlashi FG, Thomas I, Rogers JE, Bhutani MS, Lee JH, Weston B, Minsky BD, Estrella JS, Blum Murphy MA, Matamoros A, Devine CE, Das P, Badgwell BD, Ajani JA, Nogueras-Gonz?les GM. Potentially curable gastric adenocarcinoma treated without surgery. Eur J Cancer. 2018 07; 98:23-29. PMID: 29859338.
      Citations: 5     Fields:    Translation:Humans
    191. Amlashi FG, Wang X, Davila RE, Maru DM, Bhutani MS, Lee JH, Weston BR, Mizrak Kaya D, Vassilakopoulou M, Harada K, Blum Murphy MA, Rice DC, Hofstetter WL, Davila M, Nguyen QN, Ajani JA. Barrett's Esophagus after Bimodality Therapy in Patients with Esophageal Adenocarcinoma. Oncology. 2018; 95(2):81-90. PMID: 29843157; PMCID: PMC6067962.
      Citations: 1     Fields:    Translation:Humans
    192. Ikoma N, Estrella JS, Hofstetter W, Das P, Minsky BD, Ajani JA, Fournier KF, Mansfield P, Badgwell BD. Nodal Downstaging in Gastric Cancer Patients: Promising Survival if ypN0 is Achieved. Ann Surg Oncol. 2018 Jul; 25(7):2012-2017. PMID: 29748883; PMCID: PMC7703854.
      Citations: 12     Fields:    Translation:Humans
    193. Shen J, Ju Z, Zhao W, Wang L, Peng Y, Ge Z, Nagel ZD, Zou J, Wang C, Kapoor P, Ma X, Ma D, Liang J, Song S, Liu J, Samson LD, Ajani JA, Li GM, Liang H, Shen X, Mills GB, Peng G. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018 05; 24(5):556-562. PMID: 29736026; PMCID: PMC6076433.
      Citations: 154     Fields:    Translation:HumansAnimalsCells
    194. Ikoma N, Das P, Hofstetter W, Ajani JA, Estrella JS, Chen HC, Wang X, Callender RA, Zhu C, Roland CL, Fournier KF, Cormier JN, Mansfield P, Badgwell BD. Preoperative chemoradiation therapy induces primary-tumor complete response more frequently than chemotherapy alone in gastric cancer: analyses of the National Cancer Database 2006-2014 using propensity score matching. Gastric Cancer. 2018 11; 21(6):1004-1013. PMID: 29730720; PMCID: PMC6515902.
      Citations: 8     Fields:    Translation:Humans
    195. Oh SC, Sohn BH, Cheong JH, Kim SB, Lee JE, Park KC, Lee SH, Park JL, Park YY, Lee HS, Jang HJ, Park ES, Kim SC, Heo J, Chu IS, Jang YJ, Mok YJ, Jung W, Kim BH, Kim A, Cho JY, Lim JY, Hayashi Y, Song S, Elimova E, Estralla JS, Lee JH, Bhutani MS, Lu Y, Liu W, Lee J, Kang WK, Kim S, Noh SH, Mills GB, Kim SY, Ajani JA, Lee JS. Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat Commun. 2018 05 03; 9(1):1777. PMID: 29725014; PMCID: PMC5934392.
      Citations: 100     Fields:    Translation:HumansAnimalsCells
    196. Elimova E, Wang X, Qiao W, Sudo K, Wadhwa R, Shiozaki H, Shimodaira Y, Planjery V, Charalampakis N, Lee JH, Weston BR, Bhutani MS, Komaki R, Rice DC, Swisher SG, Blum MA, Rogers JE, Skinner HD, Maru DM, Hofstetter WL, Ajani JA. Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology. 2018; 94(6):345-353. PMID: 29705797; PMCID: PMC6067648.
      Citations:    Fields:    Translation:Humans
    197. Moehler M, Boku N, Ajani JA, Ryu MH, Guenther S, Chand V, Bang YJ, Taieb J, Ya?ez Ruiz E. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. Cancer Treat Rev. 2018 May; 66:104-113. PMID: 29730461.
      Citations: 36     Fields:    Translation:Humans
    198. Ikoma N, Estrella JS, Blum M, Das P, Chen HC, Wang X, Fournier K, Mansfield P, Ajani J, Badgwell BD. Central Lymph Node Metastasis in Gastric Cancer Is Predictive of Survival After Preoperative Therapy. J Gastrointest Surg. 2018 08; 22(8):1325-1333. PMID: 29679346; PMCID: PMC7703860.
      Citations: 4     Fields:    Translation:Humans
    199. Harada K, Baba H, Ajani JA. Recent trend in gastric cancer treatment in the USA. J Cancer Metastasis Treat. 2018 Apr 04; 4. PMID: 34113719; PMCID: PMC8188734.
      Citations: 2     
    200. Blum Murphy MA, Qiao W, Mewada N, Wadhwa R, Elimova E, Takashi T, Ho L, Phan A, Baker J, Ajani J. A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction. Am J Clin Oncol. 2018 04; 41(4):321-325. PMID: 26908161.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    201. Mizrak Kaya D, Harada K, Amlashi FG, Vasilakopoulou M, Ajani JA. Customization of therapy for gastroesophageal adenocarcinoma patients. Chronic Dis Transl Med. 2018 Mar; 4(1):8-17. PMID: 29756119; PMCID: PMC5938285.
      Citations: 1     
    202. Nelson DB, Dhupar R, Katkhuda R, Correa A, Goltsov A, Maru D, Sepesi B, Antonoff MB, Mehran RJ, Rice DC, Vaporciyan AA, Davila M, Davila R, Betancourt S, Ajani J, Hofstetter WL. Outcomes after endoscopic mucosal resection or esophagectomy for submucosal esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2018 07; 156(1):406-413.e3. PMID: 29605441.
      Citations: 3     Fields:    Translation:Humans
    203. Harada K, Yoshida N, Baba Y, Nakamura K, Kosumi K, Ishimoto T, Iwatsuki M, Miyamoto Y, Sakamoto Y, Ajani JA, Watanabe M, Baba H. Pyloroplasty may reduce weight loss 1 year after esophagectomy. Dis Esophagus. 2018 Mar 01; 31(3). PMID: 29579257.
      Citations: 4     Fields:    Translation:Humans
    204. Ikoma N, Cormier JN, Feig B, Du XL, Yamal JM, Hofstetter W, Das P, Ajani JA, Roland CL, Fournier K, Royal R, Mansfield P, Badgwell BD. Racial disparities in preoperative chemotherapy use in gastric cancer patients in the United States: Analysis of the National Cancer Data Base, 2006-2014. Cancer. 2018 03 01; 124(5):998-1007. PMID: 29393964; PMCID: PMC5937252.
      Citations: 15     Fields:    Translation:Humans
    205. Harada K, Mizrak Kaya D, Baba H, Ajani JA. Immune checkpoint blockade therapy for esophageal squamous cell carcinoma. J Thorac Dis. 2018 Feb; 10(2):699-702. PMID: 29607137; PMCID: PMC5864622.
      Citations: 3     
    206. Lopez A, Harada K, Mizrak Kaya D, Ajani JA. Current therapeutic landscape for advanced gastroesophageal cancers. Ann Transl Med. 2018 Feb; 6(4):78. PMID: 29666801; PMCID: PMC5890037.
      Citations: 3     
    207. Harada K, Mizrak Kaya D, Lopez A, Baba H, Ajani JA. Personalized therapy based on image for esophageal or gastroesophageal junction adenocarcinoma. Ann Transl Med. 2018 Feb; 6(4):80. PMID: 29666803; PMCID: PMC5890029.
      Citations: 1     
    208. Harada K, Wang X, Shimodaira Y, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Lopez A, Blum Murphy MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA. Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial. Target Oncol. 2018 02; 13(1):99-106. PMID: 29218623; PMCID: PMC5826863.
      Citations: 3     Fields:    Translation:Humans
    209. Zhao W, Ajani JA, Sushovan G, Ochi N, Hwang R, Hafley M, Johnson RL, Bresalier RS, Logsdon CD, Zhang Z, Song S. Galectin-3 Mediates Tumor Cell-Stroma Interactions by Activating Pancreatic Stellate Cells to Produce Cytokines via?Integrin Signaling. Gastroenterology. 2018 04; 154(5):1524-1537.e6. PMID: 29274868.
      Citations: 37     Fields:    Translation:HumansAnimalsCells
    210. Shiraishi Y, Fang P, Xu C, Song J, Krishnan S, Koay EJ, Mehran RJ, Hofstetter WL, Blum-Murphy M, Ajani JA, Komaki R, Minsky B, Mohan R, Hsu CC, Hobbs BP, Lin SH. Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. Radiother Oncol. 2018 07; 128(1):154-160. PMID: 29248170; PMCID: PMC5999560.
      Citations: 51     Fields:    Translation:HumansPHPublic Health
    211. Charalampakis N, Economopoulou P, Kotsantis I, Tolia M, Schizas D, Liakakos T, Elimova E, Ajani JA, Psyrri A. Medical management of gastric cancer: a 2017 update. Cancer Med. 2018 01; 7(1):123-133. PMID: 29239137; PMCID: PMC5773977.
      Citations: 67     Fields:    Translation:Humans
    212. Shimodaira Y, Slack RS, Harada K, Chen HC, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Blum MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Mares J, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA. Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial. Br J Cancer. 2018 02 06; 118(3):331-337. PMID: 29235564; PMCID: PMC5808035.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    213. Ikoma N, Cloyd J, Badgwell BD, Agnes A, Rodriguez-Bigas M, Ajani JA, You YN. Clinical features and survival of gastric cancer patients with DNA mismatch repair deficiency. J Surg Oncol. 2018 Mar; 117(4):707-709. PMID: 29228462; PMCID: PMC7726708.
      Citations: 1     Fields:    Translation:HumansCells
    214. Lopez A, Harada K, Mizrak Kaya D, Dong X, Song S, Ajani JA. Liquid biopsies in gastrointestinal malignancies: when is the big day? Expert Rev Anticancer Ther. 2018 01; 18(1):19-38. PMID: 29202614.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    215. Mizrak Kaya D, Harada K, Amlashi FG, Roy-Chowdhuri S, Estrella JS, Das P, Lee JH, Weston B, Bhutani MS, Matamoros A, Thomas I, Lin Q, Badgwell BD, Ajani JA, Nogueras-Gonz?lez GM. Risk of peritoneal metastases in patients who had negative peritoneal staging and received therapy for localized gastric adenocarcinoma. J Surg Oncol. 2018 Mar; 117(4):678-684. PMID: 29205363; PMCID: PMC5878692.
      Citations: 7     Fields:    Translation:Humans
    216. Ikoma N, Lee JH, Bhutani MS, Ross WA, Weston B, Chiang YJ, Blum MA, Sagebiel T, Devine CE, Matamoros A, Fournier K, Mansfield P, Ajani JA, Badgwell BD. Preoperative accuracy of gastric cancer staging in patient selection for preoperative therapy: race may affect accuracy of endoscopic ultrasonography. J Gastrointest Oncol. 2017 Dec; 8(6):1009-1017. PMID: 29299361; PMCID: PMC5750173.
      Citations: 11     
    217. Song S, Xie M, Scott AW, Jin J, Ma L, Dong X, Skinner HD, Johnson RL, Ding S, Ajani JA. A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma. Mol Cancer Ther. 2018 02; 17(2):443-454. PMID: 29167315; PMCID: PMC5805581.
      Citations: 50     Fields:    Translation:HumansAnimalsCells
    218. Ajani JA, Estrella JS, Chen Q, Correa AM, Ma L, Scott AW, Jin J, Liu B, Xie M, Sudo K, Shiozaki H, Badgwell B, Weston B, Lee JH, Bhutani MS, Onodera H, Suzuki K, Suzuki A, Ding S, Hofstetter WL, Johnson RL, Bresalier RS, Song S. Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors. Br J Cancer. 2018 01; 118(1):52-61. PMID: 29136404; PMCID: PMC5765229.
      Citations: 8     Fields:    Translation:HumansCells
    219. Harada K, Song S, Baba H, Ajani JA. Is phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway therapeutic target for esophageal adenocarcinoma. Shanghai Chest. 2017 Nov; 1. PMID: 30957072; PMCID: PMC6447035.
      Citations:    
    220. Ock CY, Hwang JE, Keam B, Kim SB, Shim JJ, Jang HJ, Park S, Sohn BH, Cha M, Ajani JA, Kopetz S, Lee KW, Kim TM, Heo DS, Lee JS. Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. Nat Commun. 2017 10 19; 8(1):1050. PMID: 29051489; PMCID: PMC5648801.
      Citations: 57     Fields:    Translation:HumansAnimals
    221. In H, Ravetch E, Langdon-Embry M, Palis B, Ajani JA, Hofstetter WL, Kelsen DP, Sano T. The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging. Gastric Cancer. 2018 Jan; 21(1):1-9. PMID: 28948368.
      Citations: 13     Fields:    Translation:Humans
    222. In H, Solsky I, Palis B, Langdon-Embry M, Ajani J, Sano T. Validation of the 8th Edition of the AJCC TNM Staging System for Gastric Cancer using the National Cancer Database. Ann Surg Oncol. 2017 Nov; 24(12):3683-3691. PMID: 28895113.
      Citations: 99     Fields:    Translation:Humans
    223. Blum Murphy M, Xiao L, Patel VR, Maru DM, Correa AM, G Amlashi F, Liao Z, Komaki R, Lin SH, Skinner HD, Vaporciyan A, Walsh GL, Swisher SG, Sepesi B, Lee JH, Bhutani MS, Weston B, Hofstetter WL, Ajani JA. Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. Cancer. 2017 Nov 01; 123(21):4106-4113. PMID: 28885712.
      Citations: 36     Fields:    Translation:Humans
    224. Ajani JA, Abramov M, Bondarenko I, Shparyk Y, Gorbunova V, Hontsa A, Otchenash N, Alsina M, Lazarev S, Elme A, Esko V, Verma U, Benedetti F, Aoyama T, Mizuguchi H, Makris L, Rosati G, DIGEST Study Group, Feliu J, Abdalla K. A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer. Ann Oncol. 2017 Sep 01; 28(9):2142-2148. PMID: 28911091.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    225. Bonnetain F, Adams RR, Ajani JA, Benson A, Bleiberg H, Chibaudel B, Fuchs CS, Giantonio BJ, Goldberg R, Heinemann V, Koopman M, Labianca R, Maughan T, Mitchell E, Peeters M, Punt CJA, Schmoll HJ, de Gramont A, Borg C, Diaz-Rubio E, Douillard JY, Larsen AK, Tournigand C. How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials. Ann Oncol. 2017 Sep 01; 28(9):2077-2085. PMID: 28430862.
      Citations: 13     Fields:    Translation:Humans
    226. Ikoma N, Blum M, Estrella JS, Wang X, Fournier KF, Mansfield PF, Ajani JA, Badgwell BD. Left Gastric Artery Lymph Nodes Should Be Included in D1 Lymph Node Dissection in Gastric Cancer. J Gastrointest Surg. 2017 Oct; 21(10):1563-1570. PMID: 28819789.
      Citations: 4     Fields:    Translation:Humans
    227. Badgwell B, Das P, Ajani J. Treatment of localized gastric and gastroesophageal adenocarcinoma: the role of accurate staging and preoperative therapy. J Hematol Oncol. 2017 08 15; 10(1):149. PMID: 28810883; PMCID: PMC5558742.
      Citations: 20     Fields:    Translation:Humans
    228. Harada K, Dong X, Estrella JS, Correa AM, Xu Y, Hofstetter WL, Sudo K, Onodera H, Suzuki K, Suzuki A, Johnson RL, Wang Z, Song S, Ajani JA. Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. Gastric Cancer. 2018 Jan; 21(1):31-40. PMID: 28801853.
      Citations: 37     Fields:    Translation:HumansCells
    229. Badgwell B, Blum M, Das P, Estrella J, Wang X, Ho L, Fournier K, Royal R, Mansfield P, Ajani J. Phase II Trial of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion for Peritoneal Carcinomatosis or Positive Peritoneal Cytology in Patients with Gastric Adenocarcinoma. Ann Surg Oncol. 2017 Oct; 24(11):3338-3344. PMID: 28799004.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    230. Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC, Shim JJ, Lee KW, Kim EH, Yim SY, Lee SH, Cheong JH, Jeong W, Cho JY, Kim J, Chae J, Lee J, Kang WK, Kim S, Noh SH, Ajani JA, Lee JS. Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. Clin Cancer Res. 2017 Aug 01; 23(15):4441-4449. PMID: 28747339; PMCID: PMC5785562.
      Citations: 136     Fields:    
    231. Wadhwa R, Wang X, Baladandayuthapani V, Liu B, Shiozaki H, Shimodaira Y, Lin Q, Elimova E, Hofstetter WL, Swisher SG, Rice DC, Maru DM, Kalhor N, Bhutani MS, Weston B, Lee JH, Skinner HD, Scott AW, Kaya DM, Harada K, Berry D, Song S, Ajani JA. Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients. Br J Cancer. 2017 Aug 22; 117(5):648-655. PMID: 28728163; PMCID: PMC5572179.
      Citations: 13     Fields:    Translation:HumansCells
    232. Ikoma N, Das P, Blum M, Estrella JS, Devine CE, Wang X, Fournier K, Mansfield P, Minsky BD, Ajani J, Badgwell BD. Preoperative Chemoradiation Therapy Does Not Increase Risk of Anastomotic Leak in Patients With Gastric Cancer. Int J Radiat Oncol Biol Phys. 2017 11 01; 99(3):660-666. PMID: 29280460.
      Citations: 9     Fields:    Translation:Humans
    233. Ohtsu A, Muro K, Van Cutsem E, Oh SC, Shimada Y, Hironaka S, Ajani JA, Tomasek J, Safran H, Chandrawansa K, Hsu Y, Heathman M, Khan A, Ni L, Melemed AS, Gao L, Ferry D, Fuchs CS, Tabernero J, Bodoky G. Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer. Mol Cancer Ther. 2017 10; 16(10):2215-2222. PMID: 28716815.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    234. Elimova E, Slack RS, Chen HC, Planjery V, Shiozaki H, Shimodaira Y, Charalampakis N, Lin Q, Harada K, Wadhwa R, Estrella JS, Kaya DM, Sagebiel T, Lee JH, Weston B, Bhutani M, Murphy MB, Matamoros A, Minsky B, Das P, Mansfield PF, Badgwell BD, Ajani JA. Patterns of relapse in patients with localized gastric adenocarcinoma who had surgery with or without adjunctive therapy: costs and effectiveness of surveillance. Oncotarget. 2017 Oct 06; 8(46):81430-81440. PMID: 29113402; PMCID: PMC5655297.
      Citations: 9     Fields:    
    235. Mizrak Kaya D, Wang X, Harada K, Blum Murphy MA, Das P, Minsky BD, Estrella JS, Lin Q, Amlashi FG, Lee JH, Weston B, Bhutani MS, Matamoros A, Sagebiel T, Wu CC, Rogers JE, Thomas I, Maru DM, Skinner HD, Badgwell BD, Hofstetter WL, Ajani JA. 101 Long-Term Survivors Who Had Metastatic Gastroesophageal Cancer and Received Local Consolidative Therapy. Oncology. 2017; 93(4):243-248. PMID: 28683449.
      Citations: 4     Fields:    Translation:Humans
    236. Mizrak Kaya D, Dong X, Xu Y, Estrella JS, Harada K, Lopez A, Amlashi FG, Hofstetter WL, Maru DM, Nguyen QN, Lee JH, Weston B, Bhutani MS, Erasmus JJ, Thomas I, Rogers JE, Song S, Ajani JA, Nogueras-Gonz?lez GM. Post-trimodality expression levels of metadherin (MTDH) as a prognostic biomarker for esophageal adenocarcinoma patients. Med Oncol. 2017 Aug; 34(8):135. PMID: 28685276.
      Citations: 3     Fields:    Translation:Humans
    237. Bang YJ, Cho JY, Kim YH, Kim JW, Di Bartolomeo M, Ajani JA, Yamaguchi K, Balogh A, Sanchez T, Moehler M. Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. Clin Cancer Res. 2017 Oct 01; 23(19):5671-5678. PMID: 28655793.
      Citations: 52     Fields:    Translation:HumansCTClinical Trials
    238. Xi M, Xu C, Liao Z, Chang JY, Gomez DR, Jeter M, Cox JD, Komaki R, Mehran R, Blum MA, Hofstetter WL, Maru DM, Bhutani MS, Lee JH, Weston B, Ajani JA, Lin SH. Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. Int J Radiat Oncol Biol Phys. 2017 11 01; 99(3):667-676. PMID: 29280461.
      Citations: 28     Fields:    Translation:Humans
    239. Badgwell B, Blum M, Das P, Estrella J, Wang X, Fournier K, Royal R, Mansfield P, Ajani J. Lessons learned from a phase II clinical trial of laparoscopic HIPEC for gastric cancer. Surg Endosc. 2018 01; 32(1):512. PMID: 28643069.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    240. Ikoma N, Blum M, Estrella JS, Das P, Hofstetter WL, Fournier KF, Mansfield P, Ajani JA, Badgwell BD. Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy. Gastric Cancer. 2018 Jan; 21(1):74-83. PMID: 28643144; PMCID: PMC7703858.
      Citations: 19     Fields:    Translation:Humans
    241. Ajani JA, Lee J, Sano T, Janjigian YY, Fan D, Song S. Gastric adenocarcinoma. Nat Rev Dis Primers. 2017 Jun 01; 3:17036. PMID: 28569272.
      Citations: 172     Fields:    Translation:Humans
    242. Shimodaira Y, Slack RS, Harada K, Bhutani MS, Elimova E, Staerkel GA, Sneige N, Erasmus J, Shiozaki H, Charalampakis N, Planjery V, Kaya DM, Amlashi FG, Blum MA, Skinner HD, Minsky BD, Maru DM, Hofstetter WL, Swisher SG, Mares JE, Rogers JE, Lin QD, Ross WA, Weston B, Lee JH, Ajani JA. Utility of endoscopic ultrasound-guided fine-needle aspiration of regional lymph nodes that are proximal to and far from the primary distal esophageal carcinoma. Oncotarget. 2017 Oct 03; 8(45):79356-79365. PMID: 29108314; PMCID: PMC5668047.
      Citations:    Fields:    
    243. Tong Z, Chatterjee D, Deng D, Veeranki O, Mejia A, Ajani JA, Hofstetter W, Lin S, Guha S, Kopetz S, Krishnan S, Maru D. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. Oncotarget. 2017 Apr 25; 8(17):28696-28710. PMID: 28404924; PMCID: PMC5438684.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    244. Elimova E, Lin Q, Song S, Ajani JA. Current status of ramucirumab in gastroesophageal adenocarcinoma. Future Oncol. 2017 Aug; 13(18):1585-1592. PMID: 28436242.
      Citations:    Fields:    Translation:HumansCells
    245. Harada K, Mizrak Kaya D, Baba H, Ajani JA. Recent advances in preoperative management of esophageal adenocarcinoma. F1000Res. 2017; 6:501. PMID: 28491289; PMCID: PMC5399958.
      Citations: 1     Fields:    
    246. Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, Mansoor W, Chung HC, Bodoky G, Shitara K, Phillips GDL, van der Horst T, Harle-Yge ML, Althaus BL, Kang YK, Thuss-Patience PC. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017 05; 18(5):640-653. PMID: 28343975.
      Citations: 135     Fields:    Translation:HumansCTClinical Trials
    247. Ikoma N, Chen HC, Wang X, Blum M, Estrella JS, Fournier K, Mansfield P, Ajani J, Badgwell BD. Patterns of Initial Recurrence in Gastric Adenocarcinoma in the Era of Preoperative Therapy. Ann Surg Oncol. 2017 Sep; 24(9):2679-2687. PMID: 28332034.
      Citations: 22     Fields:    Translation:Humans
    248. Yin Y, Shen Q, Zhang P, Tao R, Chang W, Li R, Xie G, Liu W, Zhang L, Kapoor P, Song S, Ajani J, Mills GB, Chen J, Tao K, Peng G. Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer. Am J Cancer Res. 2017; 7(3):473-483. PMID: 28401005; PMCID: PMC5385637.
      Citations: 24     
    249. DaVee T, Ajani JA, Lee JH. Is endoscopic ultrasound examination necessary in the management of esophageal cancer? World J Gastroenterol. 2017 Feb 07; 23(5):751-762. PMID: 28223720; PMCID: PMC5296192.
      Citations: 15     Fields:    Translation:Humans
    250. Mizrak Kaya D, Harada K, Shimodaira Y, Amlashi FG, Lin Q, Ajani JA. Advanced gastric adenocarcinoma: optimizing therapy options. Expert Rev Clin Pharmacol. 2017 Mar; 10(3):263-271. PMID: 28094573.
      Citations: 12     Fields:    Translation:Humans
    251. Gu J, Liang D, Pierzynski JA, Zheng L, Ye Y, Zhang J, Ajani JA, Wu X. D-mannose: a novel prognostic biomarker for patients with esophageal adenocarcinoma. Carcinogenesis. 2017 02 01; 38(2):162-167. PMID: 28062409.
      Citations: 9     Fields:    Translation:Humans
    252. Harada K, Mizrak Kaya D, Shimodaira Y, Song S, Baba H, Ajani JA. Translating genomic profiling to gastrointestinal cancer treatment. Future Oncol. 2017 Apr; 13(10):919-934. PMID: 28067073; PMCID: PMC5348722.
      Citations: 3     Fields:    Translation:Humans
    253. Betancourt Cuellar SL, Sabloff B, Carter BW, Benveniste MF, Correa AM, Maru DM, Ajani JA, Erasmus JJ, Hofstetter WL. Early clinical esophageal adenocarcinoma (cT1): Utility of CT in regional nodal metastasis detection and can the clinical accuracy be improved? Eur J Radiol. 2017 Mar; 88:56-60. PMID: 28189209.
      Citations: 4     Fields:    Translation:Humans
    254. Bartley AN, Washington MK, Ismaila N, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline Summary From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. J Oncol Pract. 2017 01; 13(1):53-57. PMID: 27907277.
      Citations: 2     Fields:    Translation:Humans
    255. Doll CM, Moughan J, Klimowicz A, Ho CK, Kornaga EN, Lees-Miller SP, Ajani JA, Crane CH, Kachnic LA, Okawara GS, Berk LB, Roof KS, Becker MJ, Grisell DL, Ellis RJ, Sperduto PW, Marsa GW, Guha C, Magliocco AM. Significance of Co-expression of Epidermal Growth Factor Receptor and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiotherapy: An Analysis of NRG Oncology RTOG 9811. Int J Radiat Oncol Biol Phys. 2017 03 01; 97(3):554-562. PMID: 28126304; PMCID: PMC5687248.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    256. Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017 Feb; 35(4):446-464. PMID: 28129524.
      Citations: 90     Fields:    Translation:Humans
    257. Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Am J Clin Pathol. 2016 Dec; 146(6):647-669. PMID: 28077399; PMCID: PMC6272805.
      Citations: 21     Fields:    Translation:Humans
    258. Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med. 2016 Dec; 140(12):1345-1363. PMID: 27841667.
      Citations: 27     Fields:    Translation:Humans
    259. Harada K, Mizrak Kaya D, Shimodaira Y, Song S, Baba H, Ajani JA. Proteomics approach to identify biomarkers for upper gastrointestinal cancer. Expert Rev Proteomics. 2016 Nov; 13(11):1041-1053. PMID: 27718753.
      Citations: 3     Fields:    
    260. Elimova E, Janjigian YY, Mulcahy M, Catenacci DV, Blum MA, Almhanna K, Hecht JR, Ajani JA. It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma. J Clin Oncol. 2017 02; 35(4):475-477. PMID: 28129519.
      Citations: 11     Fields:    Translation:Humans
    261. Welsh JW, Seyedin SN, Allen PK, Hofstetter WL, Ajani JA, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Nguyen QN, Minsky BD, Erasmus JJ, Lee JH, Bhutani M, Komaki RU. Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial. J Thorac Oncol. 2017 02; 12(2):375-382. PMID: 27794500.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    262. Ikoma N, Blum M, Chiang YJ, Estrella JS, Roy-Chowdhuri S, Fournier K, Mansfield P, Ajani J, Badgwell BD. Race Is a Risk for Lymph Node Metastasis in Patients With Gastric Cancer. Ann Surg Oncol. 2017 Apr; 24(4):960-965. PMID: 27778127.
      Citations: 15     Fields:    Translation:Humans
    263. Charalampakis N, Xiao L, Lin Q, Elimova E, Shimodaira Y, Harada K, Rogers JE, Mares J, Amlashi FG, Minsky BD, Das P, Hofstetter WL, Matamoros A, Sagebiel TL, Blum-Murphy MA, Lee JH, Weston B, Bhutani MS, Mansfield PF, Estrella JS, Badgwell BD, Ajani JA. Co-morbidities Rather than Age Impact Outcomes in Patients Receiving Preoperative Therapy for Gastroesophageal Adenocarcinoma. Ann Surg Oncol. 2017 Aug; 24(8):2291-2301. PMID: 27770339.
      Citations: 6     Fields:    Translation:Humans
    264. Badgwell B, Blum M, Estrella J, Ajani J. Personalised therapy for localised gastric and gastro-oesophageal adenocarcinoma. Lancet Oncol. 2016 12; 17(12):1628-1629. PMID: 27776842.
      Citations: 5     Fields:    Translation:Humans
    265. Ohtsuka M, Ling H, Ivan C, Pichler M, Matsushita D, Goblirsch M, Stiegelbauer V, Shigeyasu K, Zhang X, Chen M, Vidhu F, Bartholomeusz GA, Toiyama Y, Kusunoki M, Doki Y, Mori M, Song S, Gunther JR, Krishnan S, Slaby O, Goel A, Ajani JA, Radovich M, Calin GA. H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8-?-Catenin Signaling in Colorectal Cancer. EBioMedicine. 2016 Nov; 13:113-124. PMID: 27789274; PMCID: PMC5264449.
      Citations: 58     Fields:    Translation:HumansAnimalsCells
    266. Swisher SG, Moughan J, Komaki RU, Ajani JA, Wu TT, Hofstetter WL, Konski AA, Willett CG. Final Results of NRG Oncology RTOG 0246: An?Organ-Preserving Selective Resection Strategy in?Esophageal Cancer Patients Treated with Definitive?Chemoradiation. J Thorac Oncol. 2017 02; 12(2):368-374. PMID: 27729298; PMCID: PMC5263046.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    267. Harada K, Mizrak Kaya D, Shimodaira Y, Ajani JA. Global chemotherapy development for gastric cancer. Gastric Cancer. 2017 Mar; 20(Suppl 1):92-101. PMID: 27718136.
      Citations: 17     Fields:    Translation:Humans
    268. Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P, Denlinger CS, Fanta P, Farjah F, Fuchs CS, Gerdes H, Gibson M, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Johung KL, Keswani RN, Kleinberg LR, Korn WM, Leong S, Linn C, Lockhart AC, Ly QP, Mulcahy MF, Orringer MB, Perry KA, Poultsides GA, Scott WJ, Strong VE, Washington MK, Weksler B, Willett CG, Wright CD, Zelman D, McMillian N, Sundar H. Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 10; 14(10):1286-1312. PMID: 27697982.
      Citations: 340     Fields:    Translation:Humans
    269. Yi J, Lu L, Yanger K, Wang W, Sohn BH, Stanger BZ, Zhang M, Martin JF, Ajani JA, Chen J, Lee JS, Song S, Johnson RL. Large tumor suppressor homologs 1 and 2 regulate mouse liver progenitor cell proliferation and maturation through antagonism of the coactivators YAP and TAZ. Hepatology. 2016 11; 64(5):1757-1772. PMID: 27531557; PMCID: PMC5863546.
      Citations: 44     Fields:    Translation:AnimalsCells
    270. Mizrak Kaya D, Harada K, Ajani JA. Is targeted therapy possible for patients with gastric adenocarcinoma? Expert Opin Pharmacother. 2016 12; 17(18):2371-2374. PMID: 27652930.
      Citations: 1     Fields:    
    271. Lee KW, Lee SS, Hwang JE, Jang HJ, Lee HS, Oh SC, Lee SH, Sohn BH, Kim SB, Shim JJ, Jeong W, Cha M, Cheong JH, Cho JY, Lim JY, Park ES, Kim SC, Kang YK, Noh SH, Ajani JA, Lee JS. Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer. Clin Cancer Res. 2016 Dec 15; 22(24):6228-6235. PMID: 27654712; PMCID: PMC5458637.
      Citations: 14     Fields:    Translation:Humans
    272. Fuchs CS, Chau I, Melichar B, Safran H, Filip D, Topuzov E, Schlittler L, Udrea AA, Campbell W, Brincat S, Melemed SA, Hozak RR, Ferry D, Caldwell CW, Ajani JA, Tabernero J, Tom?ek J, Tehfe MA, Emig M. Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. Br J Cancer. 2016 10 11; 115(8):974-982. PMID: 27623234; PMCID: PMC5061911.
      Citations: 32     Fields:    Translation:Humans
    273. Elimova E, Mizrak Kaya D, Harada K, Ajani JA. Potentially Curable Cancers of the Esophagus and Stomach. Mayo Clin Proc. 2016 09; 91(9):1307-18. PMID: 27594190; PMCID: PMC5712474.
      Citations:    Fields:    Translation:Humans
    274. Elimova E, Song S, Shimodaira Y, Lin Q, Ajani JA. Exploiting Molecular and Immune Biology of Gastric and Gastroesophageal Adenocarcinomas to Discover Novel Therapeutic Targets. Ann Surg Oncol. 2016 11; 23(12):3786-3791. PMID: 27503493.
      Citations:    Fields:    Translation:Humans
    275. Al-Shamsi HO, Fahmawi Y, Dahbour I, Tabash A, Rogers JE, Mares JE, Blum MA, Estrella J, Matamoros A, Sagebiel T, Devine CE, Badgwell BD, Lin QD, Das P, Ajani JA. Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience. J Gastrointest Oncol. 2016 Aug; 7(4):499-505. PMID: 27563438; PMCID: PMC4963369.
      Citations: 6     
    276. Shiozaki H, Shimodaira Y, Elimova E, Wadhwa R, Sudo K, Harada K, Estrella JS, Das P, Badgwell B, Ajani JA. Evolution of gastric surgery techniques and outcomes. Chin J Cancer. 2016 07 26; 35(1):69. PMID: 27460019; PMCID: PMC4962398.
      Citations: 7     Fields:    Translation:Humans
    277. Ikoma N, Blum M, Chiang YJ, Estrella JS, Roy-Chowdhuri S, Fournier K, Mansfield P, Ajani JA, Badgwell BD. Survival rates in T1 and T2 gastric cancer: A Western report. J Surg Oncol. 2016 Oct; 114(5):602-606. PMID: 27439746.
      Citations: 4     Fields:    Translation:Humans
    278. Ikoma N, Blum M, Chiang YJ, Estrella JS, Roy-Chowdhuri S, Fournier K, Mansfield P, Ajani JA, Badgwell BD. Yield of Staging Laparoscopy and Lavage Cytology for Radiologically Occult Peritoneal Carcinomatosis of Gastric Cancer. Ann Surg Oncol. 2016 12; 23(13):4332-4337. PMID: 27384751.
      Citations: 27     Fields:    Translation:Humans
    279. Shiozaki H, Slack RS, Chen HC, Elimova E, Planjery V, Charalampakis N, Wadhwa R, Shimodaira Y, Skinner H, Lee JH, Weston B, Bhutani MS, Blum-Murphy M, Rogers JE, Maru DM, Matamoros A, Sagebiel T, Estrella JS, Das P, Hofstetter WL, Mares JE, Mizrak Kaya D, Harada K, Lin Q, Minsky BD, Badgwell BD, Ajani JA. Metastatic Gastroesophageal Adenocarcinoma Patients Treated with Systemic Therapy Followed by Consolidative Local Therapy: A Nomogram Associated with Long-Term Survivors. Oncology. 2016; 91(1):55-60. PMID: 27120436; PMCID: PMC4949128.
      Citations: 2     Fields:    Translation:Humans
    280. Charalampakis N, Elimova E, Wadhwa R, Shiozaki H, Shimodaira Y, Blum MA, Rogers JE, Harada K, Matamoros A, Sagebiel T, Das P, Minsky BD, Lee JH, Weston B, Bhutani MS, Estrella JS, Badgwell BD, Ajani JA, Nogueras Gonz?lez GM. The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation. Oncology. 2016; 90(5):239-47. PMID: 27046280; PMCID: PMC4870109.
      Citations: 16     Fields:    Translation:Humans
    281. Badgwell B, Blum M, Elimova E, Estrella J, Chiang YJ, Das P, Mansfield P, Ajani J. Frequency of Resection After Preoperative Chemotherapy or Chemoradiotherapy for Gastric Adenocarcinoma. Ann Surg Oncol. 2016 06; 23(6):1948-55. PMID: 26868957.
      Citations: 5     Fields:    Translation:Humans
    282. Sudo K, Wang X, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Rice DC, Lee JH, Weston B, Bhutani MS, Hiremath A, Charalampakis N, Komaki R, Blum MA, Swisher SG, Maru DM, Skinner HD, Garris JL, Rogers JE, Hofstetter WL, Ajani JA. A Nomogram to Predict Distant Metastases After Multimodality Therapy for Patients With Localized Esophageal Cancer. J Natl Compr Canc Netw. 2016 02; 14(2):173-9. PMID: 26850487.
      Citations: 4     Fields:    Translation:Humans
    283. Shimodaira Y, Harada K, Lin Q, Ajani JA. The best timing for administering systemic chemotherapy in patients with locally advanced rectal cancer. Ann Transl Med. 2016 Jan; 4(2):38. PMID: 26889491; PMCID: PMC4731594.
      Citations:    
    284. Lee J, Bass AJ, Ajani JA. Gastric Adenocarcinoma: An Update on Genomics, Immune System Modulations, and Targeted Therapy. Am Soc Clin Oncol Educ Book. 2016; 35:104-11. PMID: 27249691.
      Citations: 8     Fields:    Translation:Humans
    285. Sepesi B, Schmidt HE, Lada M, Correa AM, Walsh GL, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Ajani JA, Watson TJ, Swisher SG, Low DE, Hofstetter WL. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location. Ann Thorac Surg. 2016 Mar; 101(3):1075-80; Discussion 1080-1. PMID: 26680311.
      Citations: 5     Fields:    Translation:Humans
    286. Blum Murphy MA, Elimova E, Ajani JA. Current concepts and future potential in neoadjuvant chemotherapy for esophageal cancer. Expert Rev Gastroenterol Hepatol. 2016; 10(3):383-92. PMID: 26560689.
      Citations: 6     Fields:    Translation:Humans
    287. Shiozaki H, Elimova E, Slack RS, Chen HC, Staerkel GA, Sneige N, Shimodaira Y, Sagebiel T, Lee JH, Bhutani MS, Das P, Mansfield PF, Estrella JS, Badgwell BD, Ajani JA. Prognosis of gastric adenocarcinoma patients with various burdens of peritoneal metastases. J Surg Oncol. 2016 Jan; 113(1):29-35. PMID: 26603684.
      Citations: 15     Fields:    Translation:Humans
    288. Kneuertz PJ, Hofstetter WL, Chiang YJ, Das P, Blum M, Elimova E, Mansfield P, Ajani J, Badgwell B. Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ? Ann Surg Oncol. 2016 Feb; 23(2):626-32. PMID: 26564243.
      Citations: 3     Fields:    Translation:Humans
    289. Bahleda R, Baker J, Massard C, Gadgeel SM, Rogers JE, Izzedine H, Deutsch E, Garris JL, Khan A, Boelle E, Assadourian S, Soria JC, Ajani JA. Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies. Oncology. 2016; 90(1):10-20. PMID: 26492090.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    290. Pujara D, Mansfield P, Ajani J, Blum M, Elimova E, Chiang YJ, Das P, Badgwell B. Comprehensive geriatric assessment in patients with gastric and gastroesophageal adenocarcinoma undergoing gastrectomy. J Surg Oncol. 2015 Dec; 112(8):883-7. PMID: 26482869; PMCID: PMC5152567.
      Citations: 11     Fields:    Translation:Humans
    291. Charalampakis N, Xiao L, Elimova E, Wadhwa R, Shiozaki H, Shimodaira Y, Blum MA, Planjery V, Rogers JE, Matamoros A, Sagebiel T, Das P, Lee JH, Bhutani MS, Weston B, Estrella JS, Badgwell BD, Ajani JA. Initial Standardized Uptake Value of Positron Emission Tomography Influences the Prognosis of Patients with Localized Gastric Adenocarcinoma Treated Preoperatively. Oncology. 2015; 89(6):305-10. PMID: 26393501; PMCID: PMC4659715.
      Citations: 1     Fields:    Translation:Humans
    292. Chen Q, Song S, Wei S, Liu B, Honjo S, Scott A, Jin J, Ma L, Zhu H, Skinner HD, Johnson RL, Ajani JA. ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer. Oncotarget. 2015 Sep 22; 6(28):25883-96. PMID: 26317542; PMCID: PMC4694873.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    293. Elimova E, Ajani JA. Surgical Resection First for Localized Gastric Adenocarcinoma: Are There Adjuvant Options? J Clin Oncol. 2015 Oct 01; 33(28):3085-91. PMID: 26324361.
      Citations: 7     Fields:    Translation:Humans
    294. Elimova E, Wang X, Etchebehere E, Shiozaki H, Shimodaira Y, Wadhwa R, Planjery V, Charalampakis N, Blum MA, Hofstetter W, Lee JH, Weston BR, Bhutani MS, Rogers JE, Maru D, Skinner HD, Macapinlac HA, Ajani JA. 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. Eur J Cancer. 2015 Nov; 51(17):2545-52. PMID: 26321501; PMCID: PMC4663130.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    295. Sharma P, Katzka DA, Gupta N, Ajani J, Buttar N, Chak A, Corley D, El-Serag H, Falk GW, Fitzgerald R, Goldblum J, Gress F, Ilson DH, Inadomi JM, Kuipers EJ, Lynch JP, McKeon F, Metz D, Pasricha PJ, Peek R, Peters JH, Repici A, Seewald S, Shaheen NJ, Souza RF, Spechler SJ, Vennalaganti P, Wang K, Pech O. Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium. Gastroenterology. 2015 Nov; 149(6):1599-606. PMID: 26296479; PMCID: PMC4820399.
      Citations: 24     Fields:    Translation:Humans
    296. Elimova E, Shiozaki H, Slack RS, Chen HC, Wadhwa R, Sudo K, Charalampakis N, Hiremath A, Estrella JS, Matamoros A, Sagebiel T, Das P, Rogers JE, Garris JL, Blum MA, Badgwell B, Ajani JA. Early versus Delayed Therapy of Advanced Gastric Cancer Patients--Does It Make a Difference? Oncology. 2015; 89(4):215-20. PMID: 26159599; PMCID: PMC4580507.
      Citations: 2     Fields:    Translation:Humans
    297. Elimova E, Ajani JA. Time-to-Treatment Failure As the Primary End Point of a First-Line Advanced Gastric Cancer Randomized Trial: How Confused Would You Want Us to Be? J Clin Oncol. 2015 Jul 20; 33(21):2410. PMID: 26077236.
      Citations: 4     Fields:    Translation:Humans
    298. Badgwell B, Ajani J, Blum M, Ho L, Fournier K, Chiang YJ, Matamoros A, Das P, Mansfield P. Postoperative Morbidity and Mortality Rates are Not Increased for Patients with Gastric and Gastroesophageal Cancer Who Undergo Preoperative Chemoradiation Therapy. Ann Surg Oncol. 2016 Jan; 23(1):156-62. PMID: 26059652.
      Citations: 12     Fields:    Translation:Humans
    299. Scheulen ME, Rivera F, Jassem J, Carrato A, Moiseyenko V, Vynnychenko I, Van Laethem JL, Cascinu S, Ajani JA, Bodoky G, Prausov? J. Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS). J Gastrointest Cancer. 2015 Jun; 46(2):109-17. PMID: 25707610.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    300. Shimodaira Y, Elimova E, Wadhwa R, Shiozaki H, Charalampakis N, Planjery V, Rogers JE, Song S, Ajani JA. Ramucirumab for the treatment of gastroesophageal cancers. Expert Opin Orphan Drugs. 2015; 3(6):737-746. PMID: 27570714; PMCID: PMC5001688.
      Citations:    
    301. Sanchez-Espiridion B, Liang D, Ajani JA, Liang S, Ye Y, Hildebrandt MA, Gu J, Wu X. Identification of Serum Markers of Esophageal Adenocarcinoma by Global and Targeted Metabolic Profiling. Clin Gastroenterol Hepatol. 2015 Oct; 13(10):1730-1737.e9. PMID: 25998788; PMCID: PMC4596233.
      Citations: 17     Fields:    Translation:Humans
    302. Badgwell B, Blum M, Estrella J, Chiang YJ, Das P, Matamoros A, Fournier K, Mansfield P, Ajani J. Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy. J Am Coll Surg. 2015 Jul; 221(1):83-90. PMID: 26002780.
      Citations: 12     Fields:    Translation:Humans
    303. Badgwell B, Roy-Chowdhuri S, Chiang YJ, Matamoros A, Blum M, Fournier K, Mansfield P, Ajani J. Long-term survival in patients with metastatic gastric and gastroesophageal cancer treated with surgery. J Surg Oncol. 2015 Jun; 111(7):875-81. PMID: 25872485.
      Citations: 16     Fields:    Translation:Humans
    304. Charalampakis N, Elimova E, Shimodaira Y, Shiozaki H, Wadhwa R, Ajani JA. Biologics in combination with chemotherapy for gastric cancer: is this the answer? Expert Opin Pharmacother. 2015 May; 16(7):955-60. PMID: 25850442; PMCID: PMC4743879.
      Citations: 2     Fields:    Translation:Humans
    305. Elimova E, Wadhwa R, Shiozaki H, Sudo K, Estrella JS, Badgwell BD, Das P, Matamoros A, Song S, Ajani JA. Molecular biomarkers in gastric cancer. J Natl Compr Canc Netw. 2015 Apr; 13(4):e19-29. PMID: 26052595.
      Citations: 16     Fields:    Translation:HumansCells
    306. Neishaboori N, Wadhwa R, Elimova E, Shiozaki H, Sudo K, Charalampakis N, Hiremath A, Lee JH, Bhutani MS, Weston B, Blum MA, Rogers JE, Garris JL, Rice DC, Komaki R, Swisher SG, Skinner HD, Hofstetter WL, Ajani JA, Nogueras-Gonz?lez GM. Distribution of Resistant Esophageal Adenocarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation: Its Clinical Implications. Oncology. 2015; 89(2):65-9. PMID: 25765719; PMCID: PMC4498973.
      Citations: 1     Fields:    Translation:Humans
    307. Song S, Honjo S, Jin J, Chang SS, Scott AW, Chen Q, Kalhor N, Correa AM, Hofstetter WL, Albarracin CT, Wu TT, Johnson RL, Hung MC, Ajani JA. The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer. Clin Cancer Res. 2015 Jun 01; 21(11):2580-90. PMID: 25739674; PMCID: PMC4452384.
      Citations: 106     Fields:    Translation:HumansAnimalsCells
    308. Shiozaki H, Slack R, Sudo K, Elimova E, Wadhwa R, Chen HC, Skinner HD, Komaki R, Lee JH, Weston B, Bhutani MS, Blum MA, Rogers JE, Maru DM, Hofstetter WL, Ajani JA. Geographic distribution of regional metastatic nodes affects the outcome of trimodality-eligible patients with esophageal adenocarcinoma. Oncology. 2015; 88(6):332-6. PMID: 25765098; PMCID: PMC4449796.
      Citations:    Fields:    Translation:Humans
    309. Ajani JA, Song S, Hochster HS, Steinberg IB. Introduction. Semin Oncol. 2015 Apr; 42 Suppl 1:S1-2. PMID: 25839663.
      Citations:    Fields:    Translation:HumansCells
    310. Lin SH, Wang J, Allen PK, Correa AM, Maru DM, Swisher SG, Hofstetter WL, Liao Z, Ajani JA. A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer. J Gastrointest Oncol. 2015 Feb; 6(1):45-52. PMID: 25642337; PMCID: PMC4294819.
      Citations: 13     
    311. Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Besh S, Chao J, Das P, Denlinger C, Fanta P, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Jasperson K, Keswani RN, Kleinberg LR, Korn WM, Leong S, Lockhart AC, Mulcahy MF, Orringer MB, Posey JA, Poultsides GA, Sasson AR, Scott WJ, Strong VE, Varghese TK, Washington MK, Willett CG, Wright CD, Zelman D, McMillian N, Sundar H, National comprehensive cancer network. Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw. 2015 Feb; 13(2):194-227. PMID: 25691612.
      Citations: 142     Fields:    Translation:Humans
    312. Ajani JA, Hochster HS, Steinberg IB, Song S. Cancer stem cells: the promise and the potential. Semin Oncol. 2015 Apr; 42 Suppl 1:S3-17. PMID: 25839664.
      Citations: 127     Fields:    Translation:HumansCells
    313. Ajani JA. After local therapy for esophageal cancer, should we continue to survey patients and, if so, why and how? J Natl Compr Canc Netw. 2015 Jan; 13(1):2-3. PMID: 25583763.
      Citations:    Fields:    Translation:Humans
    314. Lin SJ, Gagnon-Bartsch JA, Tan IB, Earle S, Ruff L, Pettinger K, Ylstra B, van Grieken N, Rha SY, Chung HC, Lee JS, Cheong JH, Noh SH, Aoyama T, Miyagi Y, Tsuburaya A, Yoshikawa T, Ajani JA, Boussioutas A, Yeoh KG, Yong WP, So J, Lee J, Kang WK, Kim S, Kameda Y, Arai T, Zur Hausen A, Speed TP, Grabsch HI, Tan P. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut. 2015 Nov; 64(11):1721-31. PMID: 25385008; PMCID: PMC4680172.
      Citations: 89     Fields:    Translation:HumansCells
    315. Elimova E, Shiozaki H, Wadhwa R, Sudo K, Chen Q, Estrella JS, Blum MA, Badgwell B, Das P, Song S, Ajani JA. Medical management of gastric cancer: a 2014 update. World J Gastroenterol. 2014 Oct 14; 20(38):13637-47. PMID: 25320502; PMCID: PMC4194548.
      Citations: 16     Fields:    Translation:Humans
    316. Wilke H, Muro K, Van Cutsem E, Oh SC, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A, RAINBOW Study Group, Bodoky G, Rougier P. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014 Oct; 15(11):1224-35. PMID: 25240821.
      Citations: 846     Fields:    Translation:HumansCTClinical Trials
    317. Sudo K, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Taketa T, Blum MA, Lee JH, Bhutani MS, Weston B, Ross WA, Komaki R, Rice DC, Swisher SG, Hofstetter WL, Maru DM, Skinner HD, Ajani JA. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol. 2014 Oct 20; 32(30):3400-5. PMID: 25225435; PMCID: PMC4195852.
      Citations: 27     Fields:    Translation:Humans
    318. Skinner HD, Lee JH, Bhutani MS, Weston B, Hofstetter W, Komaki R, Shiozaki H, Wadhwa R, Sudo K, Elimova E, Song S, Ye Y, Huang M, Ajani J, Wu X. A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma. Cancer. 2014 Dec 01; 120(23):3635-41. PMID: 25091571; PMCID: PMC4239178.
      Citations: 30     Fields:    Translation:Humans
    319. Taketa T, Sudo K, Correa AM, Wadhwa R, Shiozaki H, Elimova E, Campagna MC, Blum MA, Skinner HD, Komaki RU, Lee JH, Bhutani MS, Weston BR, Rice DC, Swisher SG, Maru DM, Hofstetter WL, Ajani JA. Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. J Natl Compr Canc Netw. 2014 Aug; 12(8):1139-44. PMID: 25099446.
      Citations: 6     Fields:    Translation:Humans
    320. Carter BW, Macapinlac HA, Ajani JA, Komaki R, Welsh JW, Lee JH, Swisher SG, Correa AM, Erasmus JJ, Hofstetter WL, Cuellar SL. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role? J Thorac Oncol. 2014 Aug; 9(8):1202-6. PMID: 25157774.
      Citations: 15     Fields:    Translation:Humans
    321. Siegel EM, Eschrich S, Winter K, Riggs B, Berglund A, Ajidahun A, Simko J, Moughan J, Ajani J, Magliocco A, Elahi A, Hoffe S, Shibata D. Epigenomic characterization of locally advanced anal cancer: a radiation therapy oncology group 98-11 specimen study. Dis Colon Rectum. 2014 Aug; 57(8):941-57. PMID: 25003289; PMCID: PMC4100249.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    322. Patel VR, Hofstetter WL, Correa AM, Agarwal A, Rashid A, Bhutani MS, Lin SH, Ajani JA, Swisher SG, Maru DM. Signet ring cells in esophageal adenocarcinoma predict poor response to preoperative chemoradiation. Ann Thorac Surg. 2014 Sep; 98(3):1064-71. PMID: 25038008.
      Citations: 19     Fields:    Translation:Humans
    323. Li Y, Liu Z, Liu H, Wang LE, Onodera H, Suzuki A, Suzuki K, Wadhwa R, Elimova E, Sudo K, Shiozaki H, Estrella J, Lee JS, Song S, Tan D, Ajani JA, Wei Q. Potentially functional variants in the core nucleotide excision repair genes predict survival in Japanese gastric cancer patients. Carcinogenesis. 2014 Sep; 35(9):2031-8. PMID: 24990617.
      Citations: 9     Fields:    Translation:HumansCells
    324. Sun Y, Gu J, Ajani JA, Chang DW, Wu X, Stroehlein JR. Genetic and intermediate phenotypic susceptibility markers of gastric cancer in Hispanic Americans: a case-control study. Cancer. 2014 Oct 01; 120(19):3040-8. PMID: 24962126.
      Citations: 17     Fields:    Translation:HumansCells
    325. Shiozaki H, Sudo K, Xiao L, Wadhwa R, Elimova E, Hofstetter WL, Skinner HD, Lee JH, Weston B, Bhutani MS, Blum MA, Maru DM, Ajani JA. Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer. Oncology. 2014; 86(5-6):336-9. PMID: 24925190; PMCID: PMC4105702.
      Citations: 10     Fields:    Translation:Humans
    326. Song S, Ajani JA, Honjo S, Maru DM, Chen Q, Scott AW, Heallen TR, Xiao L, Hofstetter WL, Weston B, Lee JH, Wadhwa R, Sudo K, Stroehlein JR, Martin JF, Hung MC, Johnson RL. Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties. Cancer Res. 2014 Aug 01; 74(15):4170-82. PMID: 24906622; PMCID: PMC4136429.
      Citations: 119     Fields:    Translation:HumansAnimalsCells
    327. Sudo K, Elimova E, Skinner HD, Hofstetter WL, Ajani JA. Critical appraisal of locoregional failure and systemic disease progression after preoperative chemoradiation of esophageal adenocarcinoma. Reply to R. Gertler et al. J Clin Oncol. 2014 Jul 01; 32(19):2112-3. PMID: 24868018.
      Citations:    Fields:    Translation:Humans
    328. Honjo S, Ajani JA, Scott AW, Chen Q, Skinner HD, Stroehlein J, Johnson RL, Song S. Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. Int J Oncol. 2014 Aug; 45(2):567-74. PMID: 24859412; PMCID: PMC4091970.
      Citations: 49     Fields:    Translation:HumansAnimalsCells
    329. Ajani JA, Swisher SG. Three angels are dancing on the head of the esophageal cancer pin, but shouldn't we not topple one or two? Ann Surg Oncol. 2014 Sep; 21(9):2815-6. PMID: 24756809.
      Citations:    Fields:    Translation:Humans
    330. Shen R, Liu H, Wen J, Liu Z, Wang LE, Wang Q, Tan D, Ajani JA, Wei Q. Genetic polymorphisms in the microRNA binding-sites of the thymidylate synthase gene predict risk and survival in gastric cancer. Mol Carcinog. 2015 Sep; 54(9):880-8. PMID: 24756984.
      Citations: 14     Fields:    Translation:HumansCells
    331. Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, Ajani J, Tang C, Hess K, Hamilton SR, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget. 2014 Apr 15; 5(7):1837-45. PMID: 24742823; PMCID: PMC4039117.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    332. Wadhwa R, Elimova E, Shiozaki H, Sudo K, Blum MA, Estrella JS, Chen Q, Song S, Ajani JA. Anti-angiogenic agent ramucirumab: meaningful or marginal? Expert Rev Anticancer Ther. 2014 Apr; 14(4):367-79. PMID: 24605771.
      Citations: 5     Fields:    Translation:Humans
    333. Wang Q, Liu H, Xiong H, Liu Z, Wang LE, Qian J, Muddasani R, Lu V, Tan D, Ajani JA, Wei Q. Polymorphisms at the microRNA binding-site of the stem cell marker gene CD133 modify susceptibility to and survival of gastric cancer. Mol Carcinog. 2015 Jun; 54(6):449-58. PMID: 24302553.
      Citations: 10     Fields:    Translation:Humans
    334. Amini A, Ajani J, Komaki R, Allen PK, Minsky BD, Blum M, Xiao L, Suzuki A, Hofstetter W, Swisher S, Gomez D, Liao Z, Lee JH, Bhutani MS, Welsh JW. Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. Ann Surg Oncol. 2014 Jan; 21(1):306-14. PMID: 24197760.
      Citations: 18     Fields:    Translation:Humans
    335. Blum MA, Taketa T, Sudo K, Wadhwa R, Skinner HD, Ajani JA. Chemoradiation for esophageal cancer. Thorac Surg Clin. 2013 Nov; 23(4):551-8. PMID: 24199704.
      Citations: 8     Fields:    Translation:Humans
    336. Ajani JA, Wang X, Song S, Suzuki A, Taketa T, Sudo K, Wadhwa R, Hofstetter WL, Komaki R, Maru DM, Lee JH, Bhutani MS, Weston B, Baladandayuthapani V, Yao Y, Honjo S, Scott AW, Skinner HD, Johnson RL, Berry D. ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. Mol Oncol. 2014 Feb; 8(1):142-9. PMID: 24210755; PMCID: PMC3946849.
      Citations: 55     Fields:    Translation:HumansCells
    337. Dhupar R, Correa AM, Ajani J, Betancourt S, Mehran RJ, Swisher SG, Hofstetter WL. Concordance of studies for nodal staging is prognostic for worse survival in esophageal cancer. Dis Esophagus. 2014 Nov-Dec; 27(8):770-6. PMID: 24152134.
      Citations: 3     Fields:    Translation:Humans
    338. Sudo K, Taketa T, Correa AM, Campagna MC, Wadhwa R, Blum MA, Komaki R, Lee JH, Bhutani MS, Weston B, Skinner HD, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Ajani JA. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. J Clin Oncol. 2013 Dec 01; 31(34):4306-10. PMID: 24145339; PMCID: PMC3837091.
      Citations: 20     Fields:    Translation:Humans
    339. Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 2013 Nov; 10(11):643-55. PMID: 24061039; PMCID: PMC3927982.
      Citations: 195     Fields:    Translation:HumansAnimals
    340. Wadhwa R, Taketa T, Correa AM, Sudo K, Campagna MC, Blum MA, Komaki R, Skinner H, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher S, Hofstetter WL, Ajani JA. Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance. Oncology. 2013; 85(4):204-7. PMID: 24051869.
      Citations: 13     Fields:    Translation:Humans
    341. Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, Sahmoud T, Shen L, Yeh KH, Chin K, Muro K, Kim YH, Ferry D, Tebbutt NC, Al-Batran SE, Smith H, Costantini C, Rizvi S, Lebwohl D, Van Cutsem E. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol. 2013 Nov 01; 31(31):3935-43. PMID: 24043745; PMCID: PMC5950503.
      Citations: 201     Fields:    Translation:HumansCTClinical Trials
    342. Gunderson LL, Moughan J, Ajani JA, Pedersen JE, Winter KA, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. Int J Radiat Oncol Biol Phys. 2013 Nov 15; 87(4):638-45. PMID: 24035327; PMCID: PMC3938865.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    343. Li Y, Liu Z, Liu H, Wang LE, Tan D, Ajani JA, Wei QY. ERCC1 and ERCC2 variants predict survival in gastric cancer patients. PLoS One. 2013; 8(9):e71994. PMID: 24023723; PMCID: PMC3759385.
      Citations: 17     Fields:    Translation:Humans
    344. Suzuki A, Xiao L, Taketa T, Sudo K, Wadhwa R, Blum MA, Skinner H, Komaki R, Weston B, Lee JH, Bhutani MS, Rice DC, Maru DM, Erasmus J, Swisher SG, Hofstetter WL, Ajani JA. Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation. Ann Oncol. 2013 Nov; 24(11):2854-9. PMID: 23994746.
      Citations: 5     Fields:    Translation:Humans
    345. Xu E, Gu J, Hawk ET, Wang KK, Lai M, Huang M, Ajani J, Wu X. Genome-wide methylation analysis shows similar patterns in Barrett's esophagus and esophageal adenocarcinoma. Carcinogenesis. 2013 Dec; 34(12):2750-6. PMID: 23996928; PMCID: PMC3845893.
      Citations: 21     Fields:    Translation:HumansCells
    346. Ajani JA, Xiao L, Roth JA, Hofstetter WL, Walsh G, Komaki R, Liao Z, Rice DC, Vaporciyan AA, Maru DM, Lee JH, Bhutani MS, Eid A, Yao JC, Phan AP, Halpin A, Suzuki A, Taketa T, Thall PF, Swisher SG. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2013 Nov; 24(11):2844-9. PMID: 23975663; PMCID: PMC3937600.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    347. Wang J, Wei C, Tucker SL, Myles B, Palmer M, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z, Lin SH. Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2013 Aug 01; 86(5):885-91. PMID: 23845841; PMCID: PMC3786201.
      Citations: 43     Fields:    Translation:Humans
    348. Xu E, Gong Y, Gu J, Jie L, Ajani JA, Wu X. Risk assessment of esophageal adenocarcinoma using ?-H2AX assay. Cancer Epidemiol Biomarkers Prev. 2013 Oct; 22(10):1797-804. PMID: 23904462; PMCID: PMC3824382.
      Citations: 7     Fields:    Translation:HumansCells
    349. Ajani JA, Buyse M, Lichinitser M, Gorbunova V, Bodoky G, Douillard JY, Cascinu S, Heinemann V, Zaucha R, Carrato A, Ferry D, Moiseyenko V. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. Eur J Cancer. 2013 Nov; 49(17):3616-24. PMID: 23899532.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    350. Taketa T, Xiao L, Sudo K, Suzuki A, Wadhwa R, Blum MA, Lee JH, Weston B, Bhutani MS, Skinner H, Komaki R, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Ajani JA. Propensity-based matching between esophagogastric cancer patients who had surgery and who declined surgery after preoperative chemoradiation. Oncology. 2013; 85(2):95-9. PMID: 23860252.
      Citations: 17     Fields:    Translation:Humans
    351. Ajani JA. Challenges imposed by the complexity of cancer genome. Lancet Oncol. 2013 Jul; 14(8):e291-2. PMID: 23816294.
      Citations:    Fields:    Translation:Humans
    352. Xu E, Sun W, Gu J, Chow WH, Ajani JA, Wu X. Association of mitochondrial DNA copy number in peripheral blood leukocytes with risk of esophageal adenocarcinoma. Carcinogenesis. 2013 Nov; 34(11):2521-4. PMID: 23803692; PMCID: PMC3810839.
      Citations: 19     Fields:    Translation:HumansCells
    353. Wadhwa R, Taketa T, Sudo K, Blum-Murphy M, Ajani JA. Ramucirumab: a novel antiangiogenic agent. Future Oncol. 2013 Jun; 9(6):789-95. PMID: 23718298.
      Citations: 12     Fields:    Translation:Humans
    354. Murphy CC, Correa AM, Ajani JA, Komaki RU, Welsh JW, Swisher SG, Hofstetter WL. Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma. J Gastrointest Surg. 2013 Aug; 17(8):1359-69. PMID: 23715646; PMCID: PMC4998180.
      Citations: 10     Fields:    Translation:Humans
    355. Xu Y, Ma H, Yu H, Liu Z, Wang LE, Tan D, Muddasani R, Lu V, Ajani JA, Wang Y, Wei Q. The miR-184 binding-site rs8126 T>C polymorphism in TNFAIP2 is associated with risk of gastric cancer. PLoS One. 2013; 8(5):e64973. PMID: 23724109; PMCID: PMC3665554.
      Citations: 17     Fields:    Translation:HumansCells
    356. Ajani JA, Bentrem DJ, Besh S, D'Amico TA, Das P, Denlinger C, Fakih MG, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn WM, Lockhart AC, Meredith K, Mulcahy MF, Orringer MB, Posey JA, Sasson AR, Scott WJ, Strong VE, Varghese TK, Warren G, Washington MK, Willett C, Wright CD, McMillian NR, Sundar H, National Comprehensive Cancer Network. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013 May 01; 11(5):531-46. PMID: 23667204.
      Citations: 211     Fields:    Translation:Humans
    357. Wang J, Myles B, Wei C, Chang JY, Hofstetter WL, Ajani JA, Swisher SG, Cox JD, Komaki R, Liao Z, Lin SH. Obesity and outcomes in patients treated with chemoradiotherapy for esophageal carcinoma. Dis Esophagus. 2014 Feb-Mar; 27(2):168-75. PMID: 23621168; PMCID: PMC3740061.
      Citations: 6     Fields:    Translation:Humans
    358. Taketa T, Sudo K, Wadhawa R, Blum MM, Ajani JA. Adjuvant therapy in gastric cancer: what is the optimal approach? Curr Oncol Rep. 2013 Apr; 15(2):146-51. PMID: 23355076.
      Citations: 3     Fields:    Translation:Humans
    359. Song S, Maru DM, Ajani JA, Chan CH, Honjo S, Lin HK, Correa A, Hofstetter WL, Davila M, Stroehlein J, Mishra L. Loss of TGF-? adaptor ?2SP activates notch signaling and SOX9 expression in esophageal adenocarcinoma. Cancer Res. 2013 Apr 01; 73(7):2159-69. PMID: 23536563; PMCID: PMC3745222.
      Citations: 32     Fields:    Translation:HumansAnimalsCells
    360. Wu X, Ajani JA, Gu J, Chang DW, Tan W, Hildebrandt MA, Huang M, Wang KK, Hawk E. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer Prev Res (Phila). 2013 Mar; 6(3):196-205. PMID: 23466817; PMCID: PMC3608471.
      Citations: 53     Fields:    Translation:HumansCells
    361. Wadhwa R, Taketa T, Sudo K, Blum MA, Ajani JA. Modern oncological approaches to gastric adenocarcinoma. Gastroenterol Clin North Am. 2013 Jun; 42(2):359-69. PMID: 23639645.
      Citations: 27     Fields:    Translation:HumansCells
    362. Murphy CC, Hofstetter WL, Correa AM, Ajani JA, Komaki RU, Swisher SG. Utilization of surgery in trimodality-eligible patients with locally advanced esophageal adenocarcinoma in a nonprotocol setting. Dis Esophagus. 2013 Sep-Oct; 26(7):708-15. PMID: 23350713.
      Citations: 1     Fields:    Translation:Humans
    363. Blum MA, Takashi T, Suzuki A, Ajani JA. Management of localized gastric cancer. J Surg Oncol. 2013 Mar; 107(3):265-70. PMID: 23303654.
      Citations: 14     Fields:    Translation:Humans
    364. Strong VE, D'Amico TA, Kleinberg L, Ajani J. Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers. J Natl Compr Canc Netw. 2013 Jan 01; 11(1):60-6. PMID: 23307982.
      Citations: 54     Fields:    Translation:Humans
    365. Cheedella NK, Suzuki A, Xiao L, Hofstetter WL, Maru DM, Taketa T, Sudo K, Blum MA, Lin SH, Welch J, Lee JH, Bhutani MS, Rice DC, Vaporciyan AA, Swisher SG, Ajani JA. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol. 2013 May; 24(5):1262-6. PMID: 23247658; PMCID: PMC3629896.
      Citations: 41     Fields:    Translation:Humans
    366. Murphy MA, Taketa T, Sudo K, Lee JH, Ajani JA. Surveillance for esophageal cancer: does it make sense? J Natl Compr Canc Netw. 2012 Dec 01; 10(12):1590-2. PMID: 23221793.
      Citations:    Fields:    Translation:Humans
    367. Song S, Ajani JA. The role of microRNAs in cancers of the upper gastrointestinal tract. Nat Rev Gastroenterol Hepatol. 2013 Feb; 10(2):109-18. PMID: 23165235; PMCID: PMC3855852.
      Citations: 48     Fields:    Translation:HumansAnimals
    368. Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012 Dec 10; 30(35):4344-51. PMID: 23150707; PMCID: PMC3515768.
      Citations: 144     Fields:    Translation:HumansCTClinical Trials
    369. Das P, Strong VE, Ajani JA. Adjuvant and neoadjuvant therapy for gastric cancer: taking stock of the options. Gastrointest Cancer Res. 2012 Nov; 5(6):203-4. PMID: 23293702; PMCID: PMC3533849.
      Citations: 1     
    370. Swisher S, Ajani J, Correa A, Komaki R, Hofstetter W. Minimally invasive versus open oesophagectomy for oesophageal cancer. Lancet. 2012 Sep 08; 380(9845):883; author reply 885-6. PMID: 22959377.
      Citations: 2     Fields:    Translation:Humans
    371. Skinner HD, McCurdy MR, Echeverria AE, Lin SH, Welsh JW, O'Reilly MS, Hofstetter WL, Ajani JA, Komaki R, Cox JD, Sandulache VC, Myers JN, Guerrero TM. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol. 2013 Jun; 52(5):1002-9. PMID: 22950385.
      Citations: 41     Fields:    Translation:Humans
    372. Taketa T, Correa AM, Suzuki A, Blum MA, Chien P, Lee JH, Welsh J, Lin SH, Maru DM, Erasmus JJ, Bhutani MS, Weston B, Rice DC, Vaporciyan AA, Hofstetter WL, Swisher SG, Ajani JA. Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation. Oncology. 2012; 83(5):300-4. PMID: 22964903; PMCID: PMC3832345.
      Citations: 12     Fields:    Translation:Humans
    373. Taketa T, Ohigashi S, Suzuki K, Sudo K, Shiozaki H, Suzuki A, Blum MA, Ajani JA, Onodera H. Paraneoplastic neurological syndromes associated with gastric cancer: a case report and review of the literature. Clin J Gastroenterol. 2012 Oct; 5(5):355-60. PMID: 26181075.
      Citations: 2     Fields:    
    374. Marks JL, Hofstetter W, Correa AM, Mehran RJ, Rice D, Roth J, Walsh G, Vaporciyan A, Erasmus J, Chang J, Maru D, Lee JH, Lee J, Ajani JA, Swisher SG. Salvage esophagectomy after failed definitive chemoradiation for esophageal adenocarcinoma. Ann Thorac Surg. 2012 Oct; 94(4):1126-32; discussion 1132-3. PMID: 22921233.
      Citations: 21     Fields:    Translation:Humans
    375. Zalcberg JR, Ducreux M, Ajani JA, Allum W, Aust D, Bang YJ, Cascinu S, Jankowski J, Jansen EP, Kisslich R, Lordick F, Mariette C, Moehler M, Oyama T, Roth A, Rueschoff J, Ruhstaller T, Seruca R, Stahl M, Sterzing F, van Cutsem E, van der Gaast A, van Lanschot J, Ychou M, Otto F, First St Gallen EORTC Gastrointestinal Cancer Conference 2012 Expert Panel, Lutz MP, H?lscher A. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer. 2012 Nov; 48(16):2941-53. PMID: 22921186.
      Citations: 59     Fields:    Translation:Humans
    376. Lin SH, Wang L, Myles B, Thall PF, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012 Dec 01; 84(5):1078-85. PMID: 22867894; PMCID: PMC3923623.
      Citations: 100     Fields:    Translation:Humans
    377. Hayashi Y, Xiao L, Suzuki A, Blum MA, Sabloff B, Taketa T, Maru DM, Welsh J, Lin SH, Weston B, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Ajani JA. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer. Eur J Cancer. 2012 Dec; 48(18):3396-404. PMID: 22853875; PMCID: PMC3869451.
      Citations: 6     Fields:    Translation:Humans
    378. Blum MA, Ajani JA. Chemoradiation: Gastro-oesophageal cancer--is CROSSing over so hard to do? Nat Rev Clin Oncol. 2012 Sep; 9(9):493-4. PMID: 22825372.
      Citations:    Fields:    Translation:Humans
    379. Ajani JA, Correa AM, Hofstetter WL, Rice DC, Blum MA, Suzuki A, Taketa T, Welsh J, Lin SH, Lee JH, Bhutani MS, Ross WA, Maru DM, Macapinlac HA, Erasmus J, Komaki R, Mehran RJ, Vaporciyan AA, Swisher SG. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2012 Oct; 23(10):2638-2642. PMID: 22831985; PMCID: PMC3457750.
      Citations: 27     Fields:    Translation:Humans
    380. Jiang Y, Ajani JA. Anal margin cancer: current situation and ongoing trials. Curr Opin Oncol. 2012 Jul; 24(4):448-53. PMID: 22581355.
      Citations:    Fields:    Translation:Humans
    381. Wu Y, Grabsch H, Ivanova T, Tan IB, Murray J, Ooi CH, Wright AI, West NP, Hutchins GG, Wu J, Lee M, Lee J, Koo JH, Yeoh KG, van Grieken N, Ylstra B, Rha SY, Ajani JA, Cheong JH, Noh SH, Lim KH, Boussioutas A, Lee JS, Tan P. Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. Gut. 2013 Aug; 62(8):1100-11. PMID: 22735568.
      Citations: 72     Fields:    Translation:HumansCells
    382. Suzuki A, Xiao L, Taketa T, Blum MA, Matamoros A, Chien PL, Mansfield PF, Fournier KF, Weston B, Lee JH, Bhutani MS, Estrella JS, Delclos ME, Krishnan S, Das P, Ajani JA. Localized gastric cancer treated with chemoradation without surgery: UTMD Anderson Cancer Center experience. Oncology. 2012; 82(6):347-51. PMID: 22677933.
      Citations: 3     Fields:    Translation:Humans
    383. Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, Stemmermann GN, Blanke CD, Macdonald JS. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012 Jul 01; 30(19):2327-33. PMID: 22585691; PMCID: PMC4517071.
      Citations: 305     Fields:    Translation:HumansCTClinical Trials
    384. Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG, Lang JY, Li CW, Hsu JL, Miller SA, Wang X, Lee DF, Hsu JM, Huo L, Labaff AM, Liu D, Huang TH, Lai CC, Tsai FJ, Chang WC, Chen CH, Wu TT, Buttar NS, Wang KK, Wu Y, Wang H, Ajani J, Hung MC. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell. 2012 Mar 20; 21(3):374-87. PMID: 22439934; PMCID: PMC3350095.
      Citations: 197     Fields:    Translation:HumansAnimalsCells
    385. Amini A, Xiao L, Allen PK, Suzuki A, Hayashi Y, Liao Z, Hofstetter W, Crane C, Komaki R, Bhutani MS, Lee JH, Ajani JA, Welsh J. Celiac node failure patterns after definitive chemoradiation for esophageal cancer in the modern era. Int J Radiat Oncol Biol Phys. 2012 Jun 01; 83(2):e231-9. PMID: 22436793; PMCID: PMC3795392.
      Citations: 10     Fields:    Translation:Humans
    386. Hayashi Y, Blum MA, Ajani JA. Advanced gastroesophageal carcinoma: an update on the current therapeutic landscape. Onkologie. 2012; 35(4):204-9. PMID: 22488092.
      Citations: 2     Fields:    Translation:Humans
    387. Lin SH, Komaki R, Liao Z, Wei C, Myles B, Guo X, Palmer M, Mohan R, Swisher SG, Hofstetter WL, Ajani JA, Cox JD. Proton beam therapy and concurrent chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):e345-51. PMID: 22417808; PMCID: PMC3923631.
      Citations: 40     Fields:    Translation:HumansPHPublic Health
    388. Blum MA, Ajani JA. Therapy: localized gastric cancer--a CLASSIC shift in the paradigm? Nat Rev Gastroenterol Hepatol. 2012 Mar 06; 9(4):194-5. PMID: 22392288.
      Citations: 1     Fields:    Translation:Humans
    389. Kountourakis P, Ajani JA, Davila M, Lee JH, Bhutani MS, Izzo JG. Barrett's Esophagus: A Review of Biology and Therapeutic Approaches. Gastrointest Cancer Res. 2012 Mar; 5(2):49-57. PMID: 22690258; PMCID: PMC3369601.
      Citations: 6     
    390. Ajani JA, Blum MA, Estrella JS, Das P, Fournier KF. Gastric cancer: apples will always be apples. J Clin Oncol. 2012 Mar 20; 30(9):1017-8; author reply 1019-20. PMID: 22331947.
      Citations: 3     Fields:    Translation:Humans
    391. Suzuki A, Xiao L, Hayashi Y, Blum MA, Welsh JW, Lin SH, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Erasmus J, Ajani JA. Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. Oncology. 2012; 82(2):108-13. PMID: 22328056.
      Citations: 14     Fields:    Translation:Humans
    392. Ajani JA, Swisher SG. Preoperative chemotherapy for localized squamous cell carcinoma of the esophagus? We should go back to the drawing board! Ann Surg Oncol. 2012 Jan; 19(1):3-4. PMID: 21989665.
      Citations: 4     Fields:    Translation:Humans
    393. Pan JY, Ajani JA, Gu J, Gong Y, Qin A, Quin A, Hung M, Wu X, Izzo JG. Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation. Cancer. 2012 Sep 01; 118(17):4346-53. PMID: 22213102; PMCID: PMC3831524.
      Citations: 14     Fields:    Translation:Humans
    394. Harvin JA, Lahat G, Correa AM, Lee J, Maru D, Ajani J, Marom EM, Welsh J, Bhutani MS, Walsh G, Roth J, Mehran R, Vaporciyan A, Rice D, Swisher S, Hofstetter W. Neoadjuvant chemoradiotherapy followed by surgery for esophageal adenocarcinoma: significance of microscopically positive circumferential radial margins. J Thorac Cardiovasc Surg. 2012 Feb; 143(2):412-20. PMID: 22172216.
      Citations: 9     Fields:    Translation:Humans
    395. Hayashi Y, Correa AM, Hofstetter WL, Vaporciyan AA, Mehran RJ, Rice DC, Suzuki A, Lee JH, Bhutani MS, Welsh J, Lin SH, Maru DM, Swisher SG, Ajani JA. Patients with high body mass index tend to have lower stage of esophageal carcinoma at diagnosis. Dis Esophagus. 2012 Sep-Oct; 25(7):614-22. PMID: 22150920.
      Citations: 8     Fields:    Translation:Humans
    396. Chakravarty T, Crane CH, Ajani JA, Mansfield PF, Briere TM, Beddar AS, Mok H, Reed VK, Krishnan S, Delclos ME, Das P. Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma. Int J Radiat Oncol Biol Phys. 2012 Jun 01; 83(2):581-6. PMID: 22137021.
      Citations: 17     Fields:    Translation:Humans
    397. Thosani N, Singh H, Kapadia A, Ochi N, Lee JH, Ajani J, Swisher SG, Hofstetter WL, Guha S, Bhutani MS. Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis. Gastrointest Endosc. 2012 Feb; 75(2):242-53. PMID: 22115605.
      Citations: 61     Fields:    Translation:Humans
    398. Cheong JH, Park ES, Liang J, Dennison JB, Tsavachidou D, Nguyen-Charles C, Wa Cheng K, Hall H, Zhang D, Lu Y, Ravoori M, Kundra V, Ajani J, Lee JS, Ki Hong W, Mills GB. Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther. 2011 Dec; 10(12):2350-62. PMID: 21992792; PMCID: PMC3237863.
      Citations: 128     Fields:    Translation:HumansAnimalsCells
    399. Welsh J, Settle SH, Amini A, Xiao L, Suzuki A, Hayashi Y, Hofstetter W, Komaki R, Liao Z, Ajani JA. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer. 2012 May 15; 118(10):2632-40. PMID: 22565611; PMCID: PMC3747650.
      Citations: 87     Fields:    Translation:Humans
    400. Kim JY, Correa AM, Vaporciyan AA, Roth JA, Mehran RJ, Walsh GL, Rice DC, Ajani JA, Maru DM, Bhutani MS, Welsh J, Marom EM, Swisher SG, Hofstetter WL. Does the timing of esophagectomy after chemoradiation affect outcome? Ann Thorac Surg. 2012 Jan; 93(1):207-12; discussion 212-3. PMID: 21962263; PMCID: PMC4041623.
      Citations: 26     Fields:    Translation:Humans
    401. Blum MA, Ajani JA. Many a mickle makes a muckle. Translating a gastric cancer phenotype into a bigger thing. Onkologie. 2011; 34(10):499-500. PMID: 21985847.
      Citations:    Fields:    Translation:Humans
    402. Ajani JA, Mangu PB, Burstein HJ. Peek before you treat? Is it a fantasy or reality? J Oncol Pract. 2011 Sep; 7(5):338-9. PMID: 22211134; PMCID: PMC3170070.
      Citations:    Fields:    
    403. Ajani JA, Barthel JS, Bentrem DJ, D'Amico TA, Das P, Denlinger CS, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn WM, Lockhart AC, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Varghese TK, Warren G, Washington MK, Willett C, Wright CD, National Comprehensive Cancer Network. Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw. 2011 Aug 01; 9(8):830-87. PMID: 21900218.
      Citations: 84     Fields:    Translation:Humans
    404. Ajani JA. Crescendos and decrescendos: gastric and esophageal cancers. J Natl Compr Canc Netw. 2011 Aug 01; 9(8):811-3. PMID: 21900215.
      Citations:    Fields:    Translation:Humans
    405. Glasgow RE, Ilson DH, Hayman JA, Gerdes H, Mulcahy MF, Ajani JA. Modern approaches to localized cancer of the esophagus. J Natl Compr Canc Netw. 2011 Aug 01; 9(8):902-11. PMID: 21900220.
      Citations: 3     Fields:    Translation:Humans
    406. Burstein HJ, Mangu PB, Somerfield MR, Schrag D, Samson D, Holt L, Zelman D, Ajani JA, American Society of Clinical Oncology. American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol. 2011 Aug 20; 29(24):3328-30. PMID: 21788567.
      Citations: 63     Fields:    Translation:Humans
    407. Estrella JS, Hofstetter WL, Correa AM, Swisher SG, Ajani JA, Lee JH, Bhutani MS, Abraham SC, Rashid A, Maru DM. Duplicated muscularis mucosae invasion has similar risk of lymph node metastasis and recurrence-free survival as intramucosal esophageal adenocarcinoma. Am J Surg Pathol. 2011 Jul; 35(7):1045-53. PMID: 21602659.
      Citations: 11     Fields:    Translation:Humans
    408. Welsh J, Amini A, Likhacheva A, Erasmus J J, Gomez D, Davila M, Mehran RJ, Komaki R, Liao Z, Hofstetter WL, Lee H J, Bhutani MS, Ajani JA. Update: modern approaches to the treatment of localized esophageal cancer. Curr Oncol Rep. 2011 Jun; 13(3):157-67. PMID: 21365188; PMCID: PMC4086148.
      Citations: 1     Fields:    Translation:Humans
    409. Blum M, Suzuki A, Ajani JA. A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma. Future Oncol. 2011 Jun; 7(6):715-26. PMID: 21675835.
      Citations: 10     Fields:    Translation:Humans
    410. Ajani JA, Blum MA, Welsh J, Hofstetter WL, Swisher SG. Celebrate or calibrate? We say calibrate. J Clin Oncol. 2011 Jul 01; 29(19):2732; author reply 2732-3. PMID: 21606421.
      Citations:    Fields:    Translation:Humans
    411. Khokhar NZ, Jiang Y, Benson AB, Ajani JA, Mulcahy MF. Refining docetaxel-containing therapy for gastric cancer. Gastrointest Cancer Res. 2011 May; 4(3):96-105. PMID: 22043325; PMCID: PMC3201643.
      Citations: 3     
    412. Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, Tan SH, Wu J, Lee MH, Ooi CH, Rha SY, Wong WK, Boussioutas A, Yeoh KG, So J, Yong WP, Tsuburaya A, Grabsch H, Toh HC, Rozen S, Cheong JH, Noh SH, Wan WK, Ajani JA, Lee JS, Tellez MS, Tan P. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology. 2011 Aug; 141(2):476-85, 485.e1-11. PMID: 21684283; PMCID: PMC3152688.
      Citations: 165     Fields:    Translation:Humans
    413. Swisher SG, Winter KA, Komaki RU, Ajani JA, Wu TT, Hofstetter WL, Konski AA, Willett CG. A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. Int J Radiat Oncol Biol Phys. 2012 Apr 01; 82(5):1967-72. PMID: 21507583; PMCID: PMC3796353.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    414. Welsh J, Gomez D, Palmer MB, Riley BA, Mayankkumar AV, Komaki R, Dong L, Zhu XR, Likhacheva A, Liao Z, Hofstetter WL, Ajani JA, Cox JD. Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys. 2011 Dec 01; 81(5):1336-42. PMID: 21470796; PMCID: PMC4086056.
      Citations: 48     Fields:    Translation:HumansPHPublic Health
    415. Suzuki A, Xiao L, Hayashi Y, Macapinlac HA, Welsh J, Lin SH, Lee JH, Bhutani MS, Maru DM, Hofstetter WL, Swisher SG, Ajani JA. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer. 2011 Nov 01; 117(21):4823-33. PMID: 21456015; PMCID: PMC3144261.
      Citations: 28     Fields:    Translation:Humans
    416. Cho JY, Lim JY, Cheong JH, Park YY, Yoon SL, Kim SM, Kim SB, Kim H, Hong SW, Park YN, Noh SH, Park ES, Chu IS, Hong WK, Ajani JA, Lee JS. Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res. 2011 Apr 01; 17(7):1850-7. PMID: 21447720; PMCID: PMC3078023.
      Citations: 167     Fields:    Translation:Humans
    417. Ajani JA. GCR Graduates From Nursery School on a Fast Track to Editorial Excellence. Gastrointest Cancer Res. 2011 Mar; 4(2):39. PMID: 21673873; PMCID: PMC3109889.
      Citations:    
    418. Cohen DJ, Ajani J. An expert opinion on esophageal cancer therapy. Expert Opin Pharmacother. 2011 Feb; 12(2):225-39. PMID: 21226634.
      Citations: 9     Fields:    Translation:Humans
    419. Hu Y, Correa AM, Hoque A, Guan B, Ye F, Huang J, Swisher SG, Wu TT, Ajani JA, Xu XC. Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer. 2011 Jan 01; 128(1):132-43. PMID: 20309880; PMCID: PMC2937084.
      Citations: 77     Fields:    Translation:HumansCells
    420. Welsh J, Palmer MB, Ajani JA, Liao Z, Swisher SG, Hofstetter WL, Allen PK, Settle SH, Gomez D, Likhacheva A, Cox JD, Komaki R. Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):468-74. PMID: 21123005; PMCID: PMC4028959.
      Citations: 46     Fields:    Translation:HumansPHPublic Health
    421. Kim SM, Park YY, Park ES, Cho JY, Izzo JG, Zhang D, Kim SB, Lee JH, Bhutani MS, Swisher SG, Wu X, Coombes KR, Maru D, Wang KK, Buttar NS, Ajani JA, Lee JS. Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One. 2010 Nov 30; 5(11):e15074. PMID: 21152079; PMCID: PMC2994829.
      Citations: 77     Fields:    Translation:Humans
    422. Hayashi Y, Correa AM, Hofstetter WL, Vaporciyan AA, Rice DC, Walsh GL, Mehran RJ, Lee JH, Bhutani MS, Dekovich A, Swisher SG, Ajani JA. The influence of high body mass index on the prognosis of patients with esophageal cancer after surgery as primary therapy. Cancer. 2010 Dec 15; 116(24):5619-27. PMID: 21136578.
      Citations: 20     Fields:    Translation:Humans
    423. Jiang Y, Ajani JA. Multidisciplinary management of gastric cancer. Curr Opin Gastroenterol. 2010 Nov; 26(6):640-6. PMID: 20827183.
      Citations: 20     Fields:    Translation:Humans
    424. Correa MC, Deus HF, Vasconcelos AT, Hayashi Y, Ajani JA, Patnana SV, Almeida JS. AGUIA: autonomous graphical user interface assembly for clinical trials semantic data services. BMC Med Inform Decis Mak. 2010 Oct 26; 10:65. PMID: 20977768; PMCID: PMC2987967.
      Citations: 2     Fields:    Translation:Humans
    425. Kountourakis P, Correa AM, Hofstetter WL, Lee JH, Bhutani MS, Rice DC, Komaki R, Maru DM, Ross WA, Vaporciyan A, Swisher SG, Ajani JA. Combined modality therapy of cT2N0M0 esophageal cancer: the University of Texas M. D. Anderson Cancer Center experience. Cancer. 2011 Mar 01; 117(5):925-30. PMID: 20960497; PMCID: PMC3080168.
      Citations: 17     Fields:    Translation:Humans
    426. Ben-Josef E, Moughan J, Ajani JA, Flam M, Gunderson L, Pollock J, Myerson R, Anne R, Rosenthal SA, Willett C. Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J Clin Oncol. 2010 Dec 01; 28(34):5061-6. PMID: 20956625; PMCID: PMC3018356.
      Citations: 51     Fields:    Translation:Humans
    427. Patnana SV, Murthy SB, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA. Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography. Cancer. 2010 Oct 01; 116(19):4487-94. PMID: 20629031.
      Citations: 6     Fields:    Translation:Humans
    428. Swisher SG, Hofstetter W, Komaki R, Correa AM, Erasmus J, Lee JH, Liao Z, Maru D, Mehran R, Patel S, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Ajani JA. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. Ann Thorac Surg. 2010 Sep; 90(3):892-8; discussion 898-9. PMID: 20732514.
      Citations: 23     Fields:    Translation:Humans
    429. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer. 2010 Sep 01; 116(17):4007-13. PMID: 20564111; PMCID: PMC3831519.
      Citations: 39     Fields:    Translation:Humans
    430. Kim MP, Correa AM, Lee J, Rice DC, Roth JA, Mehran RJ, Walsh GL, Ajani JA, Maru DM, Chang JY, Marom EM, Macapinlac HA, Lee JH, Vaporciyan AA, Rice T, Swisher SG, Hofstetter WL. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status. Ann Thorac Surg. 2010 Sep; 90(3):884-90; discussion 890-1. PMID: 20732513.
      Citations: 12     Fields:    Translation:Humans
    431. Gaur P, Sepesi B, Hofstetter WL, Correa AM, Bhutani MS, Watson TJ, Swisher SG, M. D. Anderson Esophageal Cancer Group, University of Rochester School of Medicine and Dentistry Foregut Group. Endoscopic esophageal tumor length: a prognostic factor for patients with esophageal cancer. Cancer. 2011 Jan 01; 117(1):63-9. PMID: 20803613.
      Citations: 22     Fields:    Translation:Humans
    432. Murthy SB, Patnana SV, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA. The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma. Oncology. 2010; 78(5-6):316-22. PMID: 20699623.
      Citations: 10     Fields:    Translation:Humans
    433. Jiang Y, Mackley H, Cheng H, Ajani JA. Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment. Biomark Med. 2010 Aug; 4(4):535-41. PMID: 20701442.
      Citations: 7     Fields:    Translation:Humans
    434. Gu J, Ajani JA, Hawk ET, Ye Y, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Wang KK, Wu X. Genome-wide catalogue of chromosomal aberrations in barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis. Cancer Prev Res (Phila). 2010 Sep; 3(9):1176-86. PMID: 20651033; PMCID: PMC3932797.
      Citations: 45     Fields:    Translation:Humans
    435. Al-Batran SE, Ajani JA. Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. Cancer. 2010 Jun 01; 116(11):2511-8. PMID: 20301114.
      Citations: 26     Fields:    Translation:Humans
    436. Shah MA, Ajani JA. Gastric cancer--an enigmatic and heterogeneous disease. JAMA. 2010 May 05; 303(17):1753-4. PMID: 20442394.
      Citations: 61     Fields:    Translation:Humans
    437. Ajani JA. In the ring with a raging bull: unresectable localized esophageal carcinoma. Onkologie. 2010; 33(5):220-1. PMID: 20502055.
      Citations: 1     Fields:    Translation:Humans
    438. Ajani JA. Resectable esophageal cancer: surgery as primary therapy is not the answer, but then, what is and why? J Clin Oncol. 2010 May 20; 28(15):e243-4; author reply e245. PMID: 20368554.
      Citations: 2     Fields:    Translation:Humans
    439. Das P, Jiang Y, Lee JH, Bhutani MS, Ross WA, Mansfield PF, Ajani JA. Multimodality approaches to localized gastric cancer. J Natl Compr Canc Netw. 2010 Apr; 8(4):417-25. PMID: 20410334.
      Citations:    Fields:    Translation:Humans
    440. Ajani JA, Correa AM, Walsh GL, Komaki R, Lee JH, Vaporciyan AA, Rice DC, Yao JC, Maru DM, Hofstetter WL, Phan AT, Swisher SG. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. Cancer. 2010 Apr 01; 116(7):1656-63. PMID: 20143431.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    441. Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Das P, Denlinger C, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn M, Meredith K, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Washington MK, Willett C, Wood DE, Wright CD, Yang G, NCCN Gastric Cancer Panel. Gastric cancer. J Natl Compr Canc Netw. 2010 Apr; 8(4):378-409. PMID: 20410333.
      Citations: 60     Fields:    Translation:Humans
    442. Zachariah B, Gwede CK, James J, Ajani J, Chin LJ, Donath D, Rosenthal SA, Kane BL, Rotman M, Berk L, Kachnic LA. Octreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: randomized RTOG trial 0315. J Natl Cancer Inst. 2010 Apr 21; 102(8):547-56. PMID: 20339140; PMCID: PMC2857801.
      Citations: 16     Fields:    Translation:Humans
    443. Overman MJ, Kazmi SM, Jhamb J, Lin E, Yao JC, Abbruzzese JL, Ho L, Ajani J, Phan A. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer. 2010 Mar 15; 116(6):1446-53. PMID: 20108336.
      Citations: 18     Fields:    Translation:Humans
    444. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010 Mar 20; 28(9):1547-53. PMID: 20159816.
      Citations: 226     Fields:    Translation:HumansCTClinical Trials
    445. Jiang Y, Mackley H, Cheng H, Ajani JA. Anal carcinoma therapy: can we improve on 5-fluorouracil/mitomycin/radiotherapy? J Natl Compr Canc Netw. 2010 Jan; 8(1):135-44. PMID: 20064295.
      Citations: 2     Fields:    Translation:Humans
    446. Javeri H, Xiao L, Rohren E, Lee JH, Liao Z, Hofstetter W, Maru D, Bhutani MS, Swisher SG, Macapinlac H, Wang X, Ajani JA. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer. 2009 Nov 15; 115(22):5184-92. PMID: 19685531.
      Citations: 24     Fields:    Translation:Humans
    447. Guan X, Zhao H, Niu J, Tang D, Ajani JA, Wei Q. The VEGF -634G>C promoter polymorphism is associated with risk of gastric cancer. BMC Gastroenterol. 2009 Oct 16; 9:77. PMID: 19835575; PMCID: PMC2771032.
      Citations: 15     Fields:    Translation:HumansCells
    448. Braiteh F, Correa AM, Hofstetter WL, Rice DC, Vaporciyan AA, Walsh GL, Roth JA, Mehran RJ, Swisher SG, Ajani JA. Association of age and survival in patients with gastroesophageal cancer undergoing surgery with or without preoperative therapy. Cancer. 2009 Oct 01; 115(19):4450-8. PMID: 19562780.
      Citations: 3     Fields:    Translation:Humans
    449. Yang H, Gu J, Wang KK, Zhang W, Xing J, Chen Z, Ajani JA, Wu X. MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res. 2009 Sep 15; 15(18):5744-52. PMID: 19737949; PMCID: PMC2745487.
      Citations: 68     Fields:    Translation:Humans